Clemson University

TigerPrints
All Dissertations

Dissertations

5-2014

Cardiovascular Tissue Engineered Constructs for
Patients With Diabetes
James Chow
Clemson University, jchow@g.clemson.edu

Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
Recommended Citation
Chow, James, "Cardiovascular Tissue Engineered Constructs for Patients With Diabetes" (2014). All Dissertations. 1370.
https://tigerprints.clemson.edu/all_dissertations/1370

This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.

CARDIOVASCULAR TISSUE ENGINEERED CONSTRUCTS FOR PATIENTS
WITH DIABETES
________________________________________________________
A Dissertation
Presented to
The Graduate School of
Clemson University
_________________________________________________________
In Partial Fulfillment
of the Requirements for the Degree
Doctor of Philosophy
Bioengineering
_________________________________________________________
by:
James Peterson Chow
May 2014
_________________________________________________________
Accepted by:
Dr. Agneta Simionescu, Committee Chair
Dr. Dan Simionescu
Dr. Martine LaBerge
Dr. Christopher Wright
Dr. John Bruch

ABSTRACT
Clinical translation of cardiovascular tissue engineering (CVTE) is rapidly
shifting from concept to application, granting a myriad of opportunities for the treatment
of cardiovascular disorder (CVD).
overcome:

There remains, however, a critical hurdle to

the application of tissue engineering to a comprised patient – more

specifically, a patient with diabetes mellitus (DM). The alarming prevalence of DM is of
great concern due to its duel threat as both a risk factor for CVD and a predictor of
biomedical device failure. Elevated levels of inflammation and impaired wound healing
are hallmarks of DM contributing to cardiomyopathy, atherosclerosis, and valve disease.
The primary focus of my research was two-fold:

1) to evaluate diabetes-related

complications to scaffolds and stem cells used for cardiovascular tissue engineering; and
2) to attenuate these complications by addition of a non-toxic matrix-binding
polyphenolic antioxidant, pentagalloyl glucose (PGG).
Two types of extracellular matrix (ECM) scaffolds were investigated in this
study: collagen-based and elastin based. In vivo biocompatibility studies revealed that
the diabetic environment invoked detrimental alterations to the matrix scaffolds including
crosslinking, advanced glycation end product (AGE) accumulation, and elevated
inflammation.

However, these complications could be mitigated by scaffold pre-

treatment with PGG. By virtue of its antioxidant properties, PGG halted diabetes-related
stiffening, AGE accumulation, inflammation, and calcification.
The effects of seeded autologous adipose stem cells (ASCs) were also
investigated in vivo.

	
  

We observed immunomodulatory capabilities of ASCs to the
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implanted constructs by reducing the pro-inflammatory response, shifting the polarization
of macrophages towards constructive remodeling, and preventing inflammation-driven
calcification. The combination of ASCs with PGG formed a truly diabetic-resistant
construct capable of combating glycoxidation, crosslinking, destructive inflammation,
and calcification.
The overall goal of this research was to establish the framework of clinical
translation of tissue engineering. Tissue engineering is often heralded as a patienttailored approach for disease treatment; however, our translational efforts are useless if
we cannot address the comorbidities associated with the patient. This research takes a
step towards the development of a deliverable and robust tissue engineered construct for
use in treatment of cardiovascular disease.
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CHAPTER 1: REVIEW OF LITERATURE
1.1. The Rise and Impact of Diabetes
Diabetes Mellitus (DM) is quickly gaining prominence as an epidemic disease and a
major risk factor for the occurrence of cardiovascular diseases (CVD). Patients with DM
tend to have a significantly greater frequency of CVD along with surgical interventions
for CVD repair. In 2011, the Center for Disease Control (CDC) estimated 25.6 million
people (8.3% of the US population) with diabetes. Of these, 18.8 million were diagnosed
and 7.0 million were undiagnosed. An estimated 79 million people were considered to
have prediabetes, a precursor to type 2 DM1. More alarming, the prevalence of DM is
not just limited to the US; it is spreading worldwide to high population countries such as
China, India, and parts of the Middle East. The worldwide prevalence of diabetes was
estimated to be 2.8% (171 million) in 2000 and is expected to rise to 4.4% (366 million)
by the year 2030. In the US, it is expected to more than double from 5.6% in 2005 to
12% by the year 20502.
The socioeconomic impact of diabetes will have a major effect on healthcare costs
and insurance policies, especially if numbers continue to rise. In 2007, the total cost of
diabetes was $174 billion in both direct and indirect costs3. That same year, it was
pronounced the 7th leading cause of death in the US. It was noted that the risk of death
among people with diabetes was twice that of people of similar age, but without diabetes.
This ranking is based on the 71,382 death certificates in 2007 in which diabetes was the
underlying cause of death. These numbers do no include the additional 160,022 death
certificates where diabetes was listed as a contributing cause of a death3.
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Diabetes is a major factor in promoting elevated frequencies of CVD. This situation is a
vicious cycle that requires diabetic patients to have more surgeries for repair or
replacement of major cardiovascular features such as heart valves and blood vessels.
Such surgery has been documented to be more problematic in diabetic patients4.

1.2. Clinical Focus and Characterization of Diabetes Mellitus
DM is categorized into three main classes: type 1, type 2, and gestational. Type 1
DM is an autoimmune disorder wherein pancreatic beta cells are destroyed thus resulting
in lack of insulin production. Type 2 DM, formerly known as adult-onset diabetes, is the
most prevalent form of DM, accounting for 90 – 95% of all diagnosed cases of DM in
adults1. Type 2 DM is characterized by insulin resistance and eventual inability for
pancreatic insulin production.

Gestational diabetes is characterized by glucose

intolerance during pregnancy. The exact cause of gestational DM remains unclear;
however, it is believed to be influenced by a combination of risk factors such as obesity
and hormone imbalances5. In each class, DM is characterized by high levels of glucose
in the bloodstream caused by either lack of insulin or insulin resistance (Fig 1.1).

Figure 1.1. Elevated glucose molecules circulating in the bloodstream (hyperglycemia)
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1.2.1. Management and Treatment
Currently there is no comprehensive cure for diabetes. The best strategy lies with a
diligent and aggressive management of blood glucose level. For patients with type 1 DM,
management includes an exogenous insulin regimen, a diabetic diet, and exercise. For
patients with type 2 DM, management includes immediate weight reduction combined
with a diabetic diet and exercise6.
Adjuvant therapy in the form of pharmaceutical medications may also be
administered if glucose management, alone, is insufficient. These drugs may be used
individually or in oral combination therapy (Table 1.1)7. Oral combination therapy,
however, also increases the occurrence and severity of respective side effects.
Sulfonylureas and meglitinides act by stimulating beta cells to secrete more insulin.
Biguanides and thiazolidinediones act by stimulating other cells (fat and muscle cells) to
become more responsive to insulin. Alpha-glucosidase inhibitors act directly on the
glucose itself to prevent its formation from the breakdown of starches.

Table 1.1. Approved drugs for the pharmacological treatment of diabetes mellitus
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DPP-4 inhibitors prevent the breakdown of GLP-1, an incretin that reduces blood glucose
levels in the body. DPP-4 inhibitors, however, are unstable and breakdown rapidly and is
thus frequently used in combination with other drugs. Thiazolidinedione medications are
a class of antihyperglycemic drug currently being investigated for the resolve of
cardiovascular

disease.

Thiazolidinedione

medications

such

as

Troglitazone,

rosiglitazone (Avandia), and pioglitazone (Actos) have been introduced into clinical
practice. Troglitazone has been withdrawn due to its hepatotoxicity effects, while the
others have yet to demonstrate adverse effects8. However until additional safety and
efficacy data are investigated, the use of these medications for the treatment of
hyperglycemia in diabetic patients is still not recommended.

1.2.2. Other Current and Investigational Treatment Options
An alternative option for treatment is organ transplantation.

Diabetes heavily

damages the kidneys and attributes to end-stage renal disease (ESRD)9. The success rate
of a renal transplant is variable; according to the American Diabetes Association, 75% of
patients live past 5 years of receiving transplantation. Though it seems like a daunting
percentage, it is overwhelmingly higher than the 33% survival rate of the patients with
ESRD who choose dialysis treatment methods. Though renal transplantation can be
risky, it still offers significant chances of survival for ESRD patients.

There are,

however, limitations including organ availability and organ matching10.
Another transplant option is pancreas transplantation. Pancreas transplantation has
demonstrated to improve the quality of life for diabetic patients and minimized secondary
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complications due to diabetes; however, there are still disadvantages including surgical
risks and the dependence on life-long immunosuppressive therapy11, 12. In the same light,
islet transplantation is another option in the realm of transplants.

Though islet

transplantation has had less success, these successes have yielded both regulated insulin
secretion and the establishment of insulin independence11. As with pancreas transplants,
islet transplantation also possesses surgical risks and immunosuppressive therapy. In
order for such transplantation to achieve clinical satisfactoriness, a clear advantage over
exogenous insulin therapy remains to be demonstrated.
Biomolecular manipulation, such as gene therapy, holds the potential key in
treating diabetes. Riedel et al. has suggested that glucagon-like peptide (GLP)-1 is a
natural peptide that can be used to effectively combat diabetes13. Delivery methods for
this peptide using gene therapy are currently being investigated so that targeted
production of GLP-1 using tissue-specific promoters can improve therapeutic efficacy13.
Furuhashi et al.14 has investigated the treatment of diabetes and atherosclerosis by the
inhibition of fatty-acid-binding protein aP2 (FABP4).

This protein is expressed in

adipocytes and macrophages, linking inflammatory and metabolic responses.

They

demonstrated in vivo that a small-molecule inhibitor aP2 can be an effective therapeutic
agent against type II diabetes and atherosclerosis.

1.3. Diabetes Biochemistry – AGEs, ROS, and RAGE
The pathogenesis of diabetes-related cardiovascular diseases is a complex and
multifaceted process14-20. Dysfunction at the cellular level induced by altered metabolites
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in the body reflects the importance to understand the biochemical interactions in the
hyperglycemic environment. It is believed that a combination of advanced glycation end
products and oxidative stress elicit adverse cellular responses, which dictate tissue and
organ disease21-25.

1.3.1. Advanced Glycation End Products (AGEs)
Advanced glycation end products (AGEs) accumulate gradually during the aging
process of a human; this accumulation is greatly accelerated in diabetes. The pathologic
formation of AGEs by diabetes is believed to be responsible for inducing the
pathogenesis of many cardiovascular disorders including coronary artery disease (CAD),
peripheral artery disease (PAD), cardiomyopathy, and valve disease9, 26-28. Glucose binds
nonenzymatically to proteins, lipids, and nucleic acids via the Maillard reaction. AGEs
are characterized for their ability to form crosslinks to and between amino groups capable
of being reduced18. In AGE formation, the reaction of proteins and glucose form a Schiff
base adduct. This Schiff base will then rearrange to form an

Figure 1.2. Schematic of AGE formation to result in the crosslink of two proteins18
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Amadori product, which at this point, is still reversible. Once the Amadori product
completes the Maillard reaction, the AGE is irreversibly formed (Fig 1.2). Oxidation
accompanies glycation and assists in the formation of permanent glycoxidation products
such as (3,4)Nε-(carboxymethyl)lysine (CML) and pentosidine29, 30.

1.3.2. Reactive Oxygen Species (ROS)
Capable of undergoing dismutation to hydrogen peroxide, reactive oxygen species
(ROS) are believed to be formed by two main pathways31. In the first pathway, ROS may
be generated along the mitochondrial respiratory chain in cells rendered dysfunctional by
AGE formation32. A recent study demonstrated that hyperglycemia-induced generation
of reactive oxygen at the mitochondrial level is the initial trigger of the vicious cycle of
oxidative stress in diabetes33. In another study by Nishikawa et al, the generation of
excess pyruvate during accelerated glycolysis under hyperglycemic conditions floods the
mitochondria and causes oxygen radicals in the respiratory chain34. The second pathway
for ROS generation lies with the autoxidation of glucose molecules to generate OHradicals. In hyperglycemia, there exists an enhanced metabolism of glucose through the
polyol pathway, which also results in enhanced production of reactive oxygen35.
Superoxide dismutase (SOD) and glutathione are natural antioxidants, which help combat
oxidation in the body. SOD converts O2- to H2O2, which is then detoxified by water to
catalase or glutathione peroxidase in the mitochondria. Glutathione reductase generates
glutathione that is used as a hydrogen donor by glutathione peroxidase during elimination
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of H2O2. In diabetes, however, SOD and glutathione peroxidase expression and activity
are significantly decreased36, 37. An aggressive assault of oxidative stress and AGE
formation combined with an impaired endogenous antioxidant defense system can lead to
devastating CVDs (Table 1.2).

1.3.3. Receptors for Advanced Glycation End Products (RAGE)
Receptors of AGEs (RAGEs) are linked with the development of atherogenesis in
diabetes. RAGE is a multiligand cell surface molecule, and its activation has been
inferred to contribute to diabetic complications including atherosclerosis38.

Soro-

Paavonen et al. has demonstrated that the deletion of RAGE, causing RAGE deficiency,
attenuates the development of atherosclerosis in diabetic apoE-/- mice, a model of
accelerated atherosclerosis39. RAGE activates both pro-inflammatory responses as well
as down-regulating cellular defense mechanisms. The ligation of RAGE with AGE
contributes to increased intracellular oxidant stress18,

38, 40

. RAGE has the ability to

sustain cellular activation; thus, RAGE is able to turn an acute pro-inflammatory
response into sustained cellular dysfunction. The sustained stress to the cell introduces
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Table 1.2. Effects of AGEs that are relevant in vascular disease and diabetes mellitus

the formation of ROS to induce further inflammation38,

41

.

For this reason, a pro-

inflammatory environment such as that found in DM can devastatingly trigger a cascade
of chronic inflammation and wound healing. Oxidative stress results in the alteration of
the pro-oxidant and anti-oxidant balance.

This perturbation of balance has been

implicated atherosclerosis in both human and animal studies42, 43. The acceleration of
atherosclerosis can also be attributed to plasma proteins such as lipoproteins being
trapped by the crosslinking of collagen molecules in blood vessels. The AGE-mediated
crosslinking can trap these unwanted plasma proteins44.
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1.4. Effect of AGEs and Oxidative Stress on CVD
AGE formation was originally thought to be specific to proteins, thus modulating a
specific signal pathway for macromolecules.

It was also believed to tag senescent

proteins for degradation and removal. However, more recent studies suggest that the
interaction of AGE modified proteins with various AGE receptors activate signal
transduction pathways that promote the expression of cytokines and growth factors
responsible for tissue repair, cell chemotaxis, and cell proliferation. This biological
response contributes to the development of vascular disease and atherosclerosis18.
Occurring both intracellularly and extracellularly, the formation of AGEs promotes
endothelial dysfunction, accelerated atherosclerosis, inflammation, and calcification19, 45.
Diabetes is also considered a major risk factor for retinopathy, neuropathy, and
nephropathy. Macrovascular disease, such as atherosclerosis, is not specific to diabetes;
however, the presence of diabetes tremendously accelerates atherosclerotic lesions and
inflammation46.

Effects of AGEs relevant to the aforementioned diseases are

summarized in Table 1.3.
Hyperglycemia impairs endothelial function by increasing ROS, attenuating NO
signaling, and inducing glycoxidative stress. Though molecular and cellular mechanisms
for diabetic vascular disease are not well understood, it is believed that endothelial
dysfunction and inflammation are the two crucial factors governing the pathophysiology
of atherothrombosis. These two factors are a link connecting mitigated
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Table 1.3. Consequence of AGE formation linked with its respective biological effect in
atherosclerosis, nephropathy, neuropathy, and retinopathy

glucose tolerance and cardiovascular disease47, 48.
Development of heart failure and early and late stage death are higher following a
myocardial infarction in diabetics than in non-diabetics27. Dyslipidemia associated with
diabetes plays a key role in the development of CAD. High levels of low-dense low
density lipoprotein (LDL) and low levels of high density lipoprotein (HDL) are wellestablished factors for the pathogenesis of atherosclerosis. High levels of free fatty acids
can cause oxidative damage of HDL and impair its function49. In addition, altered levels
of metabolic substrates and products in diabetes can perturb the function of cells that are
central to atherosclerotic lesion formation50.

Endothelial dysfunction promoted by

oxidative stress causes further atherogenesis and inflammation. Abnormal metabolites in
diabetes may also promote lesion progression due to negative effects on monocyte or
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foam cell function as well as altered signaling pathways for vascular calcification24, 51.
While vascular complications and diabetic cardiomyopathy are the hallmarks of
diabetes, this is also considered a predictor of aortic valve calcification as well as valve
stiffening and stenosis52, 53.
Furthermore, AGE interactions with specific receptors on cell surfaces (RAGE)
trigger

continuous

ROS

formation,

inflammation,

and

progressive

vascular

complications38, 22. It has also been shown that this activation of AGE-RAGE pathway
induces osteoblastic differentiation of pericytes and alter the alignment of endothelial
cells, contributing to vascular calcification54 and atherosclerosis55, respectively. AGERAGE interaction contributes to impaired angiogenesis and wound healing due to
modified basement membrane and endothelial progenitor cell interaction56. AGE-RAGE
interaction also increases the adhesion of neutrophils, contributing to the weakening of
host-defense capacity in patients with diabetes57.

1.4.1. Valve Calcification
A contribution to decreased elasticity and stenosis is calcification.

In cardiac

valves, valvular interstitial cells (VICs) are the most prevalent cells and found in all three
layers – fibrosa, spongiosa, and ventricularis – of the heart valve. These cells are known
to maintain and regulate valve integrity and functionality, but there is still much to be
explored in terms of cellular characterization. It has been suggested that there are five
identifiable

phenotypes

of

VICs

including

embryonic

progenitor

endothelial/mesenchymal cells, quiescent VICs (qVICs), actived VICs (aVICs),
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progenitor VICs (pVICs), and osteoblastic VICs (obVICs). These VICs have the ability
to convert from one form to another (Fig. 1.3)58. Heart valve calcification occurs when
VICs express osteoblastic phenotypes leading to chondrogenesis and osteogensis.
Alkaline phosphatase, osteocalcin, osteopontin, and bone sialoprotein are secreted58, 59.
The role of diabetes in shaping valve calcification has not been extremely well analyzed
until it was recently suggested that aortic valve calcification is not a passive and
degenerative process, but an active and highly regulated process52. It has been shown
that aortic valve calcification is more frequent with aging and atherosclerotic risk factors.
It is also a marker of subclinical coronary artery disease52. Because diabetes has been
known a notorious risk factor for atherosclerosis60, the link between diabetes and
accelerated valve calcification can be established.

Fig 1.3. Calcification of aortic valve leaflets causing valvular stenosis
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Fig. 1.4. Potential pathways of VIC phenotype expression

1.4.2. Vascular Calcification
In terms of vascular calcification, the same principles of osteoblastic phenotype
guiding vascular pathology can be applied as with valve pathology. Recent evidence also
suggests that arterial medial calcification in diabetes is a highly regulated and active
process, very similar to that observed in patients in end-stage renal disease (ESRD).
Vascular smooth muscle cells (VSMCs) express bone matrix proteins to facilitate the
calcification process such as osteopontin, bone sialoprotein, alkaline phosphatase,
collagen type I, and osteocalcin. It has been shown that these proteins are correlated with
the degree of both vascular calcification and diabetes9, 61. In vitro studies have shown
that high glucose levels induce cell proliferation and the expression of osteopontin in
cultured VSMCs9, 62. Hunt et al. demonstrated that the bone formation in carotid plaques
of patients correlates with diabetes63. High glucose, alone, cannot be blamed for diabetic
vascular complications, but rather a combination of high glucose, altered metabolic
activity, increased AGE formation, hyperinsulinemia, and elevated levels of fibronectin
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in the arterial media64. It has been shown that insulin and fibronectin accompanied with
high levels of glucose yields increased osteopontin secretion in rat aortic smooth muscle
cells65. Hypoxia is believed to be another factor in promoting atherosclerotic lesions.
Arterial wall hypoxia has been shown to be induced by diabetes preceding the formation
of atherosclerotic lesion in animal models66. Sodhi et al. has demonstrated that not only
does hyperglycemia induce vascular smooth muscle cell calcification, but also hypoxia in
diabetes stimulates osteopontin synthesis62. Elevated levels of oxidized LDL has been
suggested to play a role in vascular calcification in vitro67; this result may correlate to
patients with diabetes who also exhibit elevated levels of oxidized LDL due to
glycoxidation. It is unclear the underlying mechanism of pathogenesis for vascular
complication, but it is known that such vascular calcification in patients with diabetes can
be attributed to a multitude of factors including hyperglycemia, adverse cellular
stimulation, hypoxia, and glycoxidation.

1.5. Diabetes vs. Modern Intervention
The adverse effects of diabetes are not limited to the cardiovascular system. Its
effects also extend to the biomaterials and surgical procedures used to repair
cardiovascular diseases.

It has been reported that diabetic populations have worse

outcomes of percutaneous coronary interventions (PCI) and coronary artery bypass
grafting (CABG). Specifically, there are more frequent occlusions in artery bypass grafts
and angioplasty16.

Though CABG is worse among diabetic populations, it remains

preferable over angioplasty, particularly those with multivessel disease.
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Luminal

renarrowing and occlusion is a major problem after PCI113. Diabetes has also been
reported as a predictor for increased risk of long term mortality and limb loss after
revascularization surgery in patients with critical limb ischemia114. These adverse events
are associated with impaired wound healing along with increased rate of infection in
diabetic patients. There are also higher rates of restenosis with both bare-metal and drugeluting stents in diabetic populations115, 116. Diabetes mellitus has also been associated
with faster structural valve degeneration of implanted bioprosthetic valves leading to a
high risk of early and long-term mortality117.
The mechanism behind exactly how diabetes causes these complex biomaterial and
surgical-related complications is not fully understood. Diabetes is believed to inhibit
biomaterial construct integration by leading a relentless assault of inflammation,
metabolite imbalance, dysfunctional cell remodeling, and oxidative stress. Furthermore
the ability of diabetes to impair wound healing ensures lack of integration of the
biomaterial as well as introduces other risks such as infection and mortality.

1.6. Tissue Engineering – Paradigm and Principles
Tissue engineering holds vast potential for the treatment of CVD; much progress is
being made in the engineering of blood vessels, heart valves, and cardiac muscle68. The
ultimate goal of tissue engineering is to replace diseased tissue with a biocompatible
tissue that has the ability regenerate over time, integrate with the patient, and restore
physiological function. The basic tenets of tissue engineering include the creation of a
suitable scaffold, repopulation of the scaffold with appropriate cells, and physiologic
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preconditioning in a bioreactor69,

70

.

Tissue engineering and regenerative medicine

therapies are considered patient-tailored because the regenerative capacity and host-tissue
integration is specific to the patient. Therefore in such cases, no immunomatching or
immunosuppressive medication is necessary due to the guided natural restoration of both
structure and function of diseased tissue. The selection of biological scaffolds for tissue
engineering applications must include considerations in biocompatibility, bioresorbability
(with safe by-products), and high porosity (to allow cell growth, waste removal, and
nutrient supply)69, 71. It is important also to optimize scaffold porosity with scaffold
mechanical strength so that the tissue may be stable enough to suit function.
By no means is it an “easy” feat to create a suitable, alternative cardiovascular
component (such as a cardiac valve), much less make it conform to native biological
function. For instance, the aortic valve can be considered the most stressed tissue in the
body – it undergoes a lifetime of continuous cyclic loading and unloading. Synthetically
engineered replacements tend to fail when subjected to demanding conditions, whereas
tissue engineering holds the potential to provide a cardiac valve capable of growing,
repairing, and remodeling while maintaining proper mechanical function over a lifetime.
The preservation of this mechanical function post implantation is crucial to the longevity
of both the construct and the patient; failure of the construct could yield life-threatening
situations for the patient72.

1.6.1. Tissue Engineering vs. Current Engineering
Much progress has been made in the engineering of cardiovascular components
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such as blood vessels, heart valves, and myocardium68, 71. Currently, adults needing
replacement of diseased tissue, such as valves, will receive either a bioprosthetic valve
(xenografts, allografts, or autografts) or a mechanical valve (Fig 1.5). Both types of
replacements have heralded varying levels of success and enhanced quality of life73.
Unfortunately, both valve types have their own respective limitations. For instance,
mechanical valves require life-long anticoagulation to prevent the chances of thrombosis
and distal embolism.

Bioprosthetic valves are prone to calcification and structural

compromise71, 74.

Fig. 1.5. Examples
of bioprosthetic
porcine valve (left)
and biomechanical
bi-leaflet valve
(right)

As previously mentioned, most bioprosthetic valves commercially available are:
(1) porcine xenograft based, (2) bovine pericardial based, and (3) allograft or autograft
valves. The porcine xenograft is comprised of a whole pig aortic valve treated in lowconcentration gluteraldehyde75. Often, this valve is configured with integrated suture
rings to make anchoring and fixation more stable. The bovine pericardial valves are also
based on glutaraldehyde treated tissues. Glutaraldehyde serves to reduce antigenicity,
stabilize the tissue to prevent from degradation, and give it mechanical strength71, 76. The
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homograft valves are preserved human valves, usually cryopreserved, which are cut and
trimmed to size prior to transplantation74, 77. It is important to note, however, that
regardless of treatments and implant procedure, the bioprosthetic valves will never be
100 percent immune from disease and calcification. The same rationale can be applied to
the mechanical valves.

There have been great strides in polymer and materials

fabrication. However, all materials will undergo some biocompatibility response and
elicit adverse reactions such as thrombosis, hematoma, embolism, and wound healing71,
74, 76

. Tissue engineering options seek to remedy these adverse issues seen in conventional

replacement options (Table 1.4)
Perhaps the most relevant and dire is the need for a suitable replacement of
vascular tissues, particularly small-diameter78. A myriad of synthetic (ePTFE, PET,
polyurethanes, PGA and PLA) and bioprosthetic grafts (autograft, allograft, xenograft)
have been developed (Fig. 1.6), but there remains an unmet clinical need of smalldiameter vascular grafts79. Such grafts must exhibit excellent mechanical properties
including adequate burst-pressure strength, suture retention strength, and compliance. In
addition to possessing adequate mechanical properties, these grafts must also be noncytotoxic, yield safe degradation products, possess long-term patency, and exhibit
resistance to thrombosis and calcification80-82. While great advances have been made in
large and medium caliber vascular grafts, small-diameter grafts have seen little
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Table 1.4. Features of conventional valve replacement vs. tissue engineered replacement71

Fig 1.6. Example of synthetic vascular graft made from ePTFE (by W.L. Gore)
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success. A tissue engineered small-diameter vascular graft is a viable option for the
replacement of peripheral and coronary vasculature, especially when demanded by an
aggressive atheroprone environment elicited by diabetes14, 83.

1.6.2. Biologic Scaffolds for Tissue Engineering
Biologic scaffolds have been proposed as a unique scaffold source due to
characteristics such as biocompatibility, biodegradability with safe by-products,
mechanical stability, and natural ECM architecture69.

Biologic scaffolds derived from

allogeneic or xenogeneic sources have piqued much interest since they can be eliminated
of cells and immunogenic material while simultaneously retaining matrix integrity,
mechanical properties, and key cell signaling molecules.
ECM-based scaffolds have been popularly used in tissue engineering applications
due to its natural architecture as being a biological scaffold in tissues and organs. ECM
is the natural framework during tissue maintenance and reconstruction following injury.
It is also part of the constructive tissue remodeling during scar tissue formation. The
three dimensional architecture of ECM is what sets it apart from traditional synthetic
scaffolds. The constructive remodeling capabilities of ECM scaffolds lies with its ability
to be quickly and completely degraded84. To process the ECM scaffold, the xenogeneic
tissue must be rendered acellular via decellularization process to remove all cellular
epitopes and cellular debris – anything that would elicit an immunogenic response.
Various detergents and enzymatic agents have been widely used in decellularization
procedures. Commonly used decellularization techniques for heart valves include a non-
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ionic detergent, Triton X-100, an anionic detergent, SDS (sodium dodecyl sulfate), and
an enzymatic agent, trypsin85-87. Other enzymatic agents such as deoxyriboneclease and
ribonuclease have been used to fully digest away nucleic acids88. The decellularization of
vascular components such as arteries has also utilized detergents such as Triton X-100
and SDS. Another decellularization agent that has shown to eliminate both cells and
collagen is sodium hydroxide. This decellularization method leaves the vascular elastin
intact to achieve a mostly elastin ECM scaffold89. It is therefore important to note that
there are various decellularization methods being used – each method may be utilized to
achieve a unique extracellular matrix scaffold. Decellularization techniques must be
carefully performed so as to not jeopardize structural integrity of the ECM while
simultaneously eliminating immunogenic rejection85.

1.6.3. Stem cells for Tissue Engineering
After an appropriate scaffold has been developed, the next step is the revitalization
of these scaffolds with appropriate stem cells and then the exposure of this construct to
mechanical and biochemical cues to spur differentiation into specific target cells. These
cells may come from several sources – embryonic, adult mesenchymal, or adult
progenitor – all of which are capable of self-renewal and differentiation into a variety of
cell types. The cells used for seeding the developing tissue must be non-immunogenic,
easy to proliferate, easy to harvest, and able to be differentiated into tissue-specific cells
to carry out specialized actions69. Patient autologous cells provide the most reliable
source of cells due to the eliminated risk of immunorejection.
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The drawbacks to

autologous cells, particularly in elderly patients, include limited availability, timeconsuming cell expansion, high variability, and weakened proliferative capacity. These
cells can come from one of five sources: (1) differentiated cells from primary tissues, (2)
adult stem cells, (3) bone marrow stromal cells, (4) bone marrow derived, circulating
stem cells, and (5) embryonic stem cells69, 90.
Typically in tissue engineering, the appropriate, undifferentiated cells are seeded
onto the scaffold whereupon stimulation of cell growth and differentiation takes place in
vitro. Thus once implantation in vivo is performed, the entire construct will be able to
remodel and establish itself as native, functional tissue91. In the cardiovascular realm,
one of the most important cell types is the endothelial cell. The endothelium forms a
monolayer to line the entire vascular system to provide a non-thrombogenic, bloodcontacting surface as well as provides a medium for the regulation of immune reactions,
nutrients, and inflammation. The endothelium also regulates the growth of other cells,
namely smooth muscle cells in the tunica media of vasculature19. Vascular smooth
muscle cells (VSMCs) are also a vital component of the vascular system. They are
responsible for the vasoconstriction and vasodilation of vessels, synthesis of collagen,
elastin, and proteoglycans. Under normal conditions VSMCs proliferate at a very slow
rate with low synthetic activity92, but are also capable of exhibiting high plasticity in
phenotype as a result of environmental changes and stimuli93. There is strong evidence
that this phenotypic switching of VSMCs and alteration of characteristic function is what
leads to vascular disease, such as atherosclerosis92, 93. In heart valves, the major cell
population is comprised of valvular interstitial cells (VICs). VICs are responsible for the
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secretion of collagen types I and III, glycosaminoglycans (GAGs), and other matrix
components. Not only do they secrete matrix products, but they also contribute matrix
degrading enzymes such as matrix metalloproteinases (MMPs) and GAG-degrading
enzymes for remodeling capabilities94-97. As mentioned before, VICs display a wide
range of phenotypes, all of which exhibit varying function; one particular phenotype
expressed by the obVIC is believed to be responsible for valvular disease
(calcification)58. Duplication of a structure where cells and matrix work together in a
symbiotic relationship is the goal of tissue engineers.
Adipose-derived stem cells (ADSCs), has until recently, been an underappreciated
source of stem cells98. The principal advantage of adipose tissue as a cell source is the
ease at which it can be obtained with minimal morbidity. ADSCs have shown the
potential for multilineage differentiation as well as the expression of multiple growth
factors98, 99. Adipose tissue may easily be obtained via minimally invasive liposuction
procedures, and the cells obtained come in large quantities (50 times more than that of
bone-marrow biopsies)99. ADSCs have also shown the potential for differentiation into
endothelial cells, cardiac muscle cells, smooth muscle cells, and VIC-like cells100.
ADSCs also show amazing potential for use in vascular tissue engineering101,

102

.

Adipose tissue is easily obtained via minimally invasive techniques such as liposuction or
lipectomy with negligible morbidity. Clinically relevant cell numbers obtained from
lipectomy is significantly higher than that from bone marrow biopsies (approximately
50X more), suggesting the possibility for the elimination of in vitro cell expansion.
ADSCs have demonstrated the potential for differentiation into smooth muscle cells,
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endothelial cells, and fibroblasts especially once isolated from the stromal vascular
fraction99,

101

. The phenotypic characteristics of ADSCs are similar to that of bone

marrow stromal cells99.
The use of human embryonic stem cells still remains a topic for ethical debate;
however, these cells are still actively being investigated.

Their multipotency is

considered much more expanse and would eliminate the hassle of cell phenotype preselection69. Embryonic stem cells have shown particular potential for differentiation into
vascular endothelial cells103. Much more investigation in the characterization of these
cells and the extent of differentiation abilities contributing to function is still needed
before their use becomes clinically significant in tissue engineering applications.

1.6.4. Bioreactors and Conditioning
Prior to functional implantation into either preclinical or clinical models, the stem
cell-revitalized scaffold must be adequately preconditioned to ensure construct
maturation and stem cell differentiation into target vascular cells. Much effort has been
devoted to the development of a suitable bioreactor to induce both physiologically
relevant mechanical forces such as shear stress, pulsatile flow, pressure104-106. In addition
to providing mechanical stimuli to the construct, biomechanical stimuli such as growth
factors may also be added to the medium to encourage stem cell differentiation toward a
specific cell lineage. The goal of the bioreactor is to replicate pertinent environmental
factors as seen in the human biologic system and ease the transition of the tissue
engineered construct from in vitro to in vivo. The combination of mechanotransduction
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and growth factor signaling in the bioreactor is expected to allow stem cells to adjust and
adapt to their new environmental niche and begin guided differentiation and construct
remodeling.
Mass transport of selected biochemicals such as oxygen and growth factors may be
provided in the bioreactor along with mechanical stimulation such as pulsatile stress,
shear stress, tension, and compression to elicit an appropriate physiological cell
phenotype and morphology69,

107, 108

.

The bioreactor is responsible for initial cell

viability, proliferation, and ECM structure remodeling in revitalized tissue engineered
constructs. Recent studies have shown that pulsatile stress during incubation upreglates
ECM deposition109.
Bioreactors have been developed for dynamic preconditioning of various
cardiovascular components such as vascular grafts105, heart valves (Fig. 1.7)

110

, and

myocardial patches111. Early bioreactors were designed to pump culture medium to
nourish the developing tissue. With the development of bioreactor technology came the
dynamic conditions to simulate physiological relevant environments. Pulsatile flow is
popular design input as it has been shown to promote the increase of mechanical
strength109 and modulation of cellular function112. While progress is being made to guide
stem cells towards appropriate differentiation, there are still some obstacles to overcome
such as lack of control, sterility, and the inability to tailor to device-specific variability109.
However, because mechanical forces and control of culture medium with various
stimulants and growth factors are so central to cellular proliferation and phenotypic
expression, the use of ever-improving bioreactors vital to tissue survival.
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Figure 1.7. Heart valve bioreactor designed for
in vitro testing and conditioning of valves.
Courtesy of Lee Sierad.

1.7. Cardiovascular Tissue Engineering Treatments for Diabetic Patients
While tissue engineering has the potential to cure diabetes (i.e. tissue engineered
pancreas), the end goal of cardiovascular tissue engineering is to make such tissue
engineering methods a viable option for diabetic patients with CVD. The promise tissue
engineering holds for the treatment of cardiovascular disorders would be rendered useless
if it did not take into consideration the complications associated with the comorbidities of
the patient (e.g. diabetes). As it stands, very little information exists on the fate of tissue
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engineered constructs in patients with diabetes. Tissue engineering has been met with
some dramatic failures in the past such as the Synergraft™ decellularized porcine heart
valve in pediatric patients118. In diabetic patients, surgeries and organ transplantation
have demonstrated to be more problematic4.

Thus the challenge of a viable tissue

engineered device combined with the challenge of diabetic conditions poses a serious
obstacle.

Taking both factors into consideration, tissue engineered scaffolds and

components are expected to fail comprehensively in diabetic conditions. It is, therefore,
necessary to tailor such cardiovascular tissue engineered constructs to become resistant to
diabetes and its associated glycoxidation, oxidative stress, and adverse cellular reactions.
Several possibilities exist for making CVTE a valid consideration for diabetic patients.

1.7.1. AGE Breakers
The restriction of the Maillard reaction with the use of “AGE breakers” have been
proposed as a potential means of deglycating proteins, lipids, and nucleic acids45. These
“AGE breakers” would be Amadoriase enzymes and other agents capable of reversing the
Amadori products formed by the Maillard reaction. Examples of such AGE breakers
include ALT-711 (dimethyl-3-phenacyl-thiazolium chloride) and pyridoxamine; these
agents are capable of breaking dicarbonyl bonds responsible for crosslinking during
glycation119, 120. There are, however, several shortcomings indicating that the concept of
AGE breakers is a flawed concept. ALT-711, though able to break dicarbonyl bonds, has
only been able to target 1,4-dideoxy-2,3-dioxoglucosone crosslink precursor; this target
has not been found to form during the Maillard reaction23. ALT-711 has also been found

	
  

28	
  

unable to cleave AGE-crosslinks in vitro and in vivo121. More investigation on cleaving
agents similar to ALT-711 is needed, specifically with the purpose of breaking the
crosslinkages associated with AGE-modified proteins caused by diabetes.

1.7.2. Antioxidants
The use of antioxidant treatment in diabetes also has potential in giving tissue
engineered constructs a fighting chance for viability.

Decreased anti-oxidant

mechanisms combined with the increased generation of free radicals is believed to cause
the oxidative stress associated with diabetes by increasing levels of reactive oxygen
species122. Studies have proven that stobadine (STB), a synthetic pyridoindole, is an
efficient antioxidant123. STB was shown to have a protective effect against glycoxidative
damage in vitro124 and matrix collagen crosslinking125. The use of STB, however, would
not be localized to the site of cardiovascular repair, but rather function as a non-specific
antioxidant. Furthermore, its effects are not permanent and only aid in preventing or
delaying long term cardiovascular diabetic complications122. Another use of antioxidants
pertains to the treatment of CVTE scaffolds to protect ECM scaffolds from protein
glycoxidation. One such treatment includes the use of phenolic tannins to not only
stabilize the scaffold, but also to render the scaffold resistant to harmful hyperglycemic
effects. Polyphenols are strong antioxidants, inhibit proteases, and reduce inflammation
and antigenicity126. Furthermore polyphenols, particularly penta-galloyl glucose (PGG),
has been shown to have a high affinity for proline-rich proteins of elastin and collagen88,
89, 127, 128
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88

and elastin scaffolds89 have

used PGG as a stabilization agent. Much more investigation is needed in determining the
efficacy of phenolic coatings of CVTE constructs as a means to achieve diabetic
resistance of scaffolds.
Protective effects of antioxidant treatments for endothelial and vascular aspects have
been elucidated by several literature reviews24, 32, 130, 131. Physiological antioxidants such
as superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and catalase (CAT)
are responsible for regulating the amount of reactive oxygen species.

In diabetes,

however, these biological enzymes are not only overloaded with free radicals, but also
their production is compromised due to cellular dysfunction and damage. Exogenous
antioxidant treatment such as vitamin E24, rutin132, and green tea catechins133 have also
seen limited success in the prevention of diabetes-related complications. These successes
have been observed more so in the laboratory setting rather than the clinical setting.
Treating the antioxidant vitamins as a single class of compounds with expected similar
effects inappropriately disregards their wide range of chemical properties and
pharmacodynamics130. Most clinical trials focus on the use of vitamin E.

1.7.3. Polyphenols – PGG
There has been comprehensive examination of the detrimental effects of diabetes
on cardiovascular collagen and elastin scaffolds, but also elucidation of a promising
solution to the diabetes-related complications – the use of a matrix-binding polyphenol
antioxidant, PGG

134

.

PGG is a gallotannin with five ester bonds formed between

carboxylic groups of gallic acids and aliphatic hydroxyl groups of a glucose core (Fig.
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1.8). Polyphenols exhibit high affinity for proline-rich proteins such as collagen and
elastin127, 128, which have open structures and form strong peptide-phenolic hydrogen
bonds.

These interactions make PGG strong candidates for stabilizing biologic

cardiovascular scaffolds. In addition to being strong antioxidants, PGG also exhibits
properties in anti-inflammation, anti-mutagenicity, anti-carcinogenicity, insulin-mimicry,
and anti-infection135-139.

Fig. 1.8. a Sterical configuration of α-PGG and β-PGG. b Structure and 3D model of β-PGG.135

Studies both in vivo and in vitro have shown that PGG exhibits multiple
biological activities, which implicate a great potential for PGG in the therapy and
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prevention of several major human diseases including cancer and diabetes. PGG has
been shown to strongly inhibit the binding of VEGF to its receptor tyrosine kinase
(DKR/Flk-1) and block VEGF-induced HUVEC proliferation and the growth of cells
thus implicating anti-cancer potential via anti-angiogenesis abilities140. Li et al reported
that both that	
   both	
   α-‐PGG	
   and	
   β-‐PGG	
   possessed	
   insulin-‐mimicking	
   activity	
   in	
   the	
  
absence	
  of	
  insulin,	
  and	
  that	
  α-‐PGG	
  was	
  more	
  potent	
  than	
  β-‐PGG.	
  	
  In	
  these	
  studies,	
  α-‐
PGG	
  itself	
  stimulated	
  glucose	
  uptake	
  in	
  3T3-‐L1	
  adipocytes	
  but	
  weakened	
  the	
  activity	
  
of	
   insulin	
   if	
   treated	
   together136.	
   	
   Tannins	
   have	
   also	
   been	
   shown	
   to	
   be	
   good	
   direct	
  
antioxidants;	
   the	
   protein-‐tannin	
   complex	
   can	
   act	
   as	
   radical	
   scavengers	
   and	
   radical	
  
sinks.	
   	
   In	
   one	
   study,	
   free	
   radical	
   scavenging	
   capability	
   has	
   shown	
   efficacy	
   more	
  
potent	
  than	
  that	
  of	
  vitamin	
  E141.	
  	
  In	
  the	
  same	
  study,	
  it	
  was	
  also	
  seen	
  to	
  inhibit	
  lipid	
  
peroxidation	
   induced	
   by	
   hydrogen	
   peroxide.	
   	
   The	
   anti-‐inflammatory	
   properties	
   of	
  
PGG	
   has	
   been	
   shown	
   to	
   attenuate	
   the	
   stimulating	
   effects	
   of	
   pro-‐inflammatory	
  
cytokines	
  such	
  as	
  TNF-‐α	
  and	
  IL-‐6142.	
  	
  Similarly,	
  PGG	
  is	
  able	
  to	
  inhibit	
  iNOS	
  activity	
  
and	
   NO	
   production	
   as	
   well	
   as	
   suppress	
   the	
   vascular	
   inflammatory	
   process	
   by	
   acting	
  
as	
  an	
  anti-‐arteriosclerosis	
  agent143,	
  144.	
  	
  While	
  the	
  mechanisms	
  underlying	
  the	
  anti-‐
inflammatory	
  effects	
  of	
  PGG	
  are	
  unclear,	
  it	
  is	
  believed	
  that	
  the	
  inhibition	
  of	
  nuclear	
  
factor-‐κB	
  (NF-‐κB)	
  plays	
  an	
  important139.

1.8. Conclusions
Progress is being made towards finding the potential cure for diabetes. Whether
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this cure lies with gene therapy, pharmaceutic therapy, or regenerative medicine still
remains unknown. It is clear, however, that patients with diabetes currently have no
pathology-specific treatment for cardiovascular disease.

Tissue engineering in the

cardiovascular realm holds immense potential for treating pathologies and disorders;
however these treatment options would be rendered ineffective if they cannot address the
complications associated with a compromised patient (e.g. a patient with DM). It is clear
that DM is a major risk factor for cardiovascular disorders such as atherosclerosis, end
stage renal disease, and calcification.

The body chemistry of a diabetic patient is

characterized by extreme levels glycoxidation and oxidative stress which can take a
devastating toll on proteins, lipids, and nucleic acids – virtually all tissues and cells
comprising the human body. Therefore, there is no reason to believe that a tissue
engineered construct would not encounter the same complications and be subjected to the
same diabetic scrutiny once implanted into the patient. While great strides are being
made in CVTE, more investigation is needed to devise a method to combat glycoxidative
conditions in order to give patients with diabetes the same opportunistic chance as
patients without diabetes.

1.9.
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CHAPTER 2: RESEARCH MOTIVATION, SPECIFIC AIMS, AND PROJECT
SIGNIFICANCE

2.1. Introduction
Clinical translation of cardiovascular tissue engineering is rapidly shifting from
concept to application, granting a myriad of opportunities for the treatment of
cardiovascular disease (CVD). There remains, however, a critical hurdle to overcome:
the application of tissue engineering to a compromised patient – more specifically, a
patient with diabetes mellitus (DM).

Diabetes poses a major risk factor for

cardiovascular diseases, particularly vascular disease.

High levels of glucose non-

enzymatically interact with extracellular matrix (ECM) proteins, such as collagen and
elastin, to form irreversible crosslinks resulting in the formation of two detriments:
advanced glycation end products (AGEs)1 and reactive oxygen species (ROS)2. AGEs
and ROS are believed to be responsible for the adverse fate of vascular disease and
vascular stiffening3. The severe cell and extracellular matrix (ECM) alterations induced
by glycoxidation lead to endothelial dysfunction, inflammation, atherosclerosis, impaired
wound healing, fibrosis, and calcification4-7 – all of which are counter-conducive to the
integration of tissue engineered constructs.
Our long-term goal is to develop tissue engineered vascular and valvular ECMbased scaffolds, revitalized with adult stem cells, which are capable of withstanding the
effects of diabetes-related glycoxidation. To achieve this goal, we will investigate the
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effects of diabetes on both collagen-elastin scaffolds and stem cells used for scaffold
revitalization as well as the protective effects of scaffold pre-treatment with polyphenols.
Preliminary studies performed in our lab have highlighted the protective effects
of pentagalloyl glucose (PGG), an antioxidant polyphenol capable of preventing the
formation of AGEs as well as lessen stiffening and calcification when implanted
subdermally into diabetic rats8.

These results have encouraged us to transition to

clinically relevant scenarios, which include the introduction of autologous stem cells to
the cardiovascular constructs. We choose to focus on vascular constructs for the in vitro
2D and bioreactor (3D) testing due to the large demand for vascular grafts and because
vascular disease in diabetes is the most devastating. We believe that by seeding
autologous stem cells onto these acellular vascular scaffolds, we will promote
differentiation and support construct remodeling into a native tissue replacement. We
hypothesize that diabetes will alter the ECM-derived scaffolds and their in vivo
remodeling, but scaffold pre-treatment with PGG and seeding with autologous stem cells
will mitigate diabetes-related complications.

2.2. Specific Aims
Aim 1:

To identify biochemical and mechanical alterations of cardiovascular

scaffolds in diabetes (Presented in Chapter 3)
Hypothesis: Diabetes induces chemical crosslinking and stiffening of the collagen and
elastin based biological scaffolds
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Approach: Normal and diabetic (STZ-induced) adult male Sprague Dawley rats will be
used for these studies. Diabetic Collagen scaffolds and elastin scaffolds will be prepared
by complete decellularization of adult porcine aortic valve leaflets and adult porcine
carotid arteries, respectively, from local abattoirs. Scaffolds will be implanted
subcutaneously on the backs of the rats and incubated for four weeks. At the end of this
time, scaffolds will be retrieved and evaluated for stiffness and crosslinking, AGE
products, host cell infiltration, and matrix remodeling.
Innovative Features: We will report for the first time on diabetes-related complications
induced to ECM-based scaffolds used for cardiovascular tissue engineering

Aim 2: To mitigate diabetes-induced alterations of cardiovascular scaffolds by
treatment with PGG (Presented in Chapter 3)
Hypothesis: PGG protects ECM proteins from irreversible cross-link formation, by
virtue of its anti-oxidative and matrix-binding properties
Approach: Similar to Aim 1, normal and diabetic (STZ-induced) adult male Sprague
Dawley rats will be used for these studies. Both collagen and elastin scaffolds will be
obtained from the same decellularization procedures as described in Aim 1.

After

decellularization, scaffolds will be mildly treated with PGG. Scaffolds will be implanted
subcutaneously on the backs of the rats and incubated for four weeks. At the end of this
time, scaffolds will be retrieved and evaluated for stiffness and crosslinking, AGE
products, host cell infiltration, and matrix remodeling.
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Innovative Features: We will report for the first time on the use of PGG as an ECMbinding agent that renders cardiovascular scaffolds resistant from diabetes-related
complications.
	
  

Aim 3:

To Evaluate the Effect of Autologous Stem Cell Seeding on Scaffold

Remodeling in Diabetic Environment (Presented in Chapter 4)
Hypothesis:

Autologous stem cells seeded on PGG-treated scaffolds will alleviate

diabetes-related inflammation and oxidation.
Approach: Adipose stem cells (ASCs) will be isolated from normal and diabetic rats
and seeded, via injection, into non-treated and PGG-treated scaffolds comprised of
collagen and elastin (see Aim 2). Seeded constructs will be placed subdermally into each
rat as scaffold-supported autologous implants. Upon four weeks, constructs will be
explanted and evaluated for phenotypic modulations, ECM degradation, mechanical
properties, glycoxidation products, and host response such as calcification and
inflammation.
Innovative Features: The fate of autologous stem cell-seeded scaffolds have not been
investigated in in vivo diabetic environments. Moreover, this will be the first reported
exploration of the immunomodulatory properties of ASCs in these scaffolds.
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Aim 4: To assess the effect of hyperglycemic environments on adipose stem cell
differentiation into target vascular cells in 2D and 3D (Presented in Chapter 5)
Hypothesis: The efficacy of differentiation of stem cells into target vascular cells will be
altered in a diabetic environment and will require pre-differentiation in a controlled
biochemical and biomechanical millieu.
Approach:

Human ASCs, obtained and expanded in either normal or diabetic

conditions, will be seeded onto all tunics of the vascular scaffold and subjected to
biomechanical stresses in a vascular bioreactor in normoglycemic and hyperglycemic
conditions. The effect of mechanical conditioning on modulations in cell phenotype will
be examined by various markers relevant to smooth muscle cells and endothelial cells.
Likewise, human ASCs will be cultured in 2D plates and subjected to growth factorenriched media to encourage either smooth muscle cell or endothelial cell differentiation.
Differentiation will be analyzed by markers relevant to endothelial cells and smooth
muscle cells.
Innovative Features:

This will be the first reported attempt to differentiate and

characterize adipose stem cells in a diabetic setting in 2D and 3D.

2.3. Significance of Proposed Project
This project is expected to have a significant impact by addressing the patienttailored approach to translational regenerative medicine. Tissue engineering therapies are
often heralded as being specifically tailored according to each patient; however, many of
these assertions neglect to address the comorbidities associated with the patient. Diabetes
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is expected to not only trigger disease, but also cause cutting edge treatments in
regenerative medicine to fail. The creation of a diabetes-resistant tissue engineered
construct for regenerative medicine will not only revolutionize the field of diseasemodeled tissue engineering, but also pave the way for a readily available and much
needed autologous valve replacements and vascular grafts for the treatment of diabetic
patients with cardiovascular disease.
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CHAPTER 3: DEVELOPMENT AND CHARACTERIZATION OF DIABETIC –
RESISTANT CARDIOVASCULAR SCAFFOLDS FOR TISSUE ENGINEERING
(This work has been published in Biomaterials, 2013. 34(3): p. 685-695)
3.1 Introduction
Diabetic hyperglycemia, resulting from the deficiency in insulin secretion (Type 1
diabetes) or insulin resistance (Type 2 diabetes), combined with dyslipidemia, oxidative
stress, and inflammation, significantly increases the risk of atherosclerotic vascular
disease1, aortic valve disease2, 3 and cardiomyopathy4. Studies have shown that, despite
great advances in diagnosis and treatment of CVD, over the last several years diabetic
patients have not shared the same decline in coronary artery disease-related mortality as
non-diabetic patients1.
The primary cause of cardiovascular tissue damage occurring in diabetes is the
formation of advanced glycation end products (AGEs), which generate irreversible crosslinks on long-lived proteins, such as collagen and elastin5, 6. Glucose and lipid molecules
undergo a series of oxidant-induced fragmentation, leading to the formation of shortchain reactive compounds that react with proteins and form AGEs, such as carboxymethyl lysine (CML) and pentosidine7. Malondialdehyde (MDA) is a marker for
oxidative stress and a well known by-product of lipid peroxidation8. AGEs impair wound
healing and induce excessive inflammation9, fibrosis, and tissue stiffness10-12. As a result,
the outcome of reparative surgery and tissue transplantation is more problematic in
diabetic patients13.
Tissue engineering holds great promise to treat cardiovascular diseases14,
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Significant progress has been made in the field of blood vessel16-18, heart valve19, 20, and
cardiac tissue engineering21, 22. It is critical that replacements for damaged cardiovascular
structures possess appropriate biomechanical properties from the outset of implantation.
Therefore, there is increased interest in collagen and elastin-based biological scaffolds
derived from xenogeneic or allogeneic extracellular matrices (ECM), which have optimal
physical properties. Furthermore, the 3D structure of the ECM can be preserved with an
optimal decellularization technique that removes cells without damaging the matrix
components23-25. Ideally, basement membrane proteins are also retained, as their presence
is essential to tissue regeneration26.
For pre-clinical evaluation, tissue engineered constructs and their remodeling are
typically tested in healthy animals27-29. However, there are great expectations that TE and
regenerative medicine research will offer solutions for patients affected by the
cardiovascular complications of diabetes. The complex glycoxidative environment could
affect tissue remodeling since the ECM proteins, especially collagen and elastin as well
as the matrix metalloproteinases (MMPs) involved in matrix remodeling, might be
modified by the formation of AGEs. Matrix alterations that result in activation of
inflammation, fibrosis, and impaired healing might not be conducive to the desired
integration and remodeling of tissue engineered constructs. These aspects can only be
assessed in diabetic animal models with very strict glycemic control30-32.
We hypothesized that AGEs could alter the properties of matrix-derived scaffolds,
such as collagen scaffolds used for heart valve tissue engineering and elastin scaffolds for
blood vessel tissue engineering. This could affect the outcome of tissue engineering
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products based on biological scaffolds.
3.2. Materials and Methods
3.2.1. Materials
Streptozotocin was from Sigma (S0130). The insulin preparation used for rats in
this study was Humulin N U- 100 NPH, Human Insulin of rDNA origin Isophane
suspension from Lilly (Indian- apolis, IN). Electrophoresis apparatus, chemicals, and
molecular weight standards were from Bio-Rad (Hercules, CA). Bicinchoninic acid
protein assay kit was from Pierce Biotech (Rockford, IL). The Vectastain Elite kit and the
ABC diaminobenzidine tetrahydrochloride peroxidase substrate kit were purchased from
Vector Laborato- ries (Burlingame, CA). We used the following antibodies: rabbit anticollagen IV (Abcam, #ab6586), rabbit anti-laminin (Abcam, #ab11575), monoclonal antiN- epsilon-(carboxymethyl)lysine (CML) antibody (MAB3247, R&D Systems), monoclonal anti-vimentin (V5255, Sigma), mouse anti-CD8 (GTX76218, GeneTex Inc, Irvine,
CA), mouse anti-CD68 anti-macrophage/monocyte antibody, clone ED-1 (MAB1435,
Millipore, Billerica, MA). Deoxyribonuclease I was from Worthington Biochemical
Corporation (Lakewood, NJ). AlphaTRAK (Gen II) test strip and the AlphaTRAK!
Blood Glucose Monitoring System was from Abbott Laboratories, Animal Health
(Abbott Park, IL). All other chemicals were of highest purity available and were obtained
from Sigma Aldrich Corporation (Lakewood, NJ).

3.2.2. Heart Valve Collagen Scaffold Preparation
Collagen scaffolds were prepared following a protocol described previously with
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minor modifications25. Briefly, fresh porcine aortic roots were harvested from a local
slaughterhouse, cleaned over ice, and placed in double-distilled water overnight at 4°C to
induce hypotonic shock and cell lysis. Next, for complete cell removal, the valves were
placed on an orbital shaker at room temperature and treated with 0.05M NaOH for 2 h
followed by 70% ethanol for 20 min and an overnight incubation in a mixture of
detergents: 0.5% sodium dodecyl sulfate, 0.5% Triton X-100, 0.5% deoxycholate, 0.2%
ethylenediaminetetra-acetic acid in 50 mM TRIS, pH7.5. After rinsing five times with
double-distilled water and 70% ethanol to remove detergents, valves were treated with
deoxyribonuclease/ribonuclease mixture (360mU/ml for each enzyme) for 2 days at
37°C, to complete the removal of nucleic acids. After rinsing with double-distilled water,
valves were sterilized in 70% ethanol overnight at room temperature. Under sterile
conditions, the aortic cusps were dissected away from the aortic wall and stored in sterile
ddH20 with 1% antibiotic/antimycotic (Pen-Strep) at 4°C. Each individual cusp served as
a collagen scaffold. This decellularization method effectively removed cells, while
preserving valve matrix components and eliminating the porcine a-Gal epitope25.

3.2.3. Arterial Elastin Scaffold Preparation
Elastin scaffolds were prepared following an alkaline extraction protocol
described before, with minor modifications24. Briefly, fresh porcine carotid arteries
(60x80 mm long, 5x6 mm diameter) obtained from Animal Technologies, Inc. (Tyler,
TX) were rendered acellular by incubation in 0.1M NaOH solution at 37°C for 24 h
followed by extensive rinsing with deionized water until pH dropped to neutral. Scaffolds
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were then rinsed and stored in sterile PBS. This treatment removed all cells and most of
the collagen, leaving vascular elastin intact. Scaffolds were also completely devoid of the
a-Gal epitope (data not shown).

3.2.4. Rat Model of STZ-Induced Diabetes
Adult male Sprague-Dawley rats (n = 20, weight 300-350 g) were rendered
diabetic via a single dose of sterile filtered 55 mg/kg streptozotocin solution in 0.1M
citrate buffer (pH 5) by tail vein injection. Control rats (n = 20) received an equal volume
of vehicle (sterile citrate buffer). Starting on day 3, levels of blood glucose were
determined 3e4 times per week, using AlphaTRAK (Gen II) test strips on the
AlphaTRAK Blood Glucose Monitoring System, designed specifically for animals.
Diabetes was established (>400 mg glucose/dL blood), and diabetic rats were given
subcutaneous injections of long-lasting insulin (2-4 U Isophane) every other day to
maintain blood glucose level in a desirable range (400-600 mg glucose/dL blood) and
prevent development of ketonuria and weight loss. Glucose levels, individual weights,
hydration status, and food and water consumption were monitored closely and
continuously graphed to ensure adequate health parameters. Animals were provided with
food and water ad libitum and were cared for by the attending university veterinarian and
associated staff at the Godley-Snell Research Center animal facility. The Animal
Research Committee at Clemson University approved the animal protocol, and National
Institute of Health (NIH) guidelines for the care and use of laboratory animals (NIH
publication #86-23 Rev. 1996) were observed throughout the experiment.
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3.2.5. Subdermal Implantation
Four weeks after STZ administration, rats were prepped for surgery and
anesthetized using 1-2% Isoflurane. A small, transverse incision was made on the back of
the rats, and two subdermal pouches were created by blunt dissection. The acellular
scaffolds were implanted – one whole acellular aortic cusp (collagen scaffold) in each
pocket (n = 2 implants per rat), and the incision was closed with surgical staples.
Acellular arteries (elastin scaffolds) were cut open longitudinally and 1 x 3 cm samples
were implanted subdermally, as described above for cusps (n = 2 per rat). Diabetic rats
were given 1U of insulin pre-operatively. The rats were allowed to recover, provided
with food and water ad libitum, and were cared for by the attending veterinarian and
associated staff at the Godley-Snell Research Center animal facility. Post-operative levels
of blood glucose were determined 3-4 times per week, and diabetic rats were given
insulin as described above. After four weeks, the rats were humanely euthanized by CO2
asphyxiation and the scaffolds explanted and collected according to their respective assay
application as follows: scaffolds for histological analysis were placed in Karnovksy’s
Fixative (2.5% glutaraldehyde, 2% formalin, 0.1M cacodylic acid, pH 7.4) and paraffin
embedded; samples designated for mechanical analysis were collected in sterile PBS with
0.02% NaN3; and samples for protein, calcium and AGE analysis were flash frozen in
liquid nitrogen and kept on dry ice until transferred to -20°C for storage.

3.2.6. Histological Analysis
Rehydrated paraffin sections (5 mm) were stained with Hematoxylin and Eosin
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(H&E) for a general overview of morphology and to confirm cellular removal. Movat’s
Pentachrome stain was used to evaluate the extracellular matrix composi- tion and
integrity after decellularization and after implantation (n 1⁄4 4 per implant group).
Immunohistochemistry (IHC) was performed for detection of laminin and type IV
collagen in acellular scaffolds, and the results were compared to native cusps and arteries
(n 1⁄4 4 per implant group). Briefly, rehydrated parrafin sections (5 mm) were exposed to
0.1% Proteinase K in 10 mM TRIS buffer, pH7.5, at room temperature for 30s to unmask
the antigens. Endogenous peroxidases were blocked with 0.3% hydrogen peroxide in
0.3% horse normal serum. Sections were treated with 0.025% Triton X-100 for 10 min
and then incubated with normal blocking serum for 20 min. Primary antibodies (rabbit
anti-laminin, 4 mg/mL dilution, or rabbit anti-collagen type IV, 2 mg/mL dilution) were
applied for 1 h at room temperature. Negative staining controls were obtained by the
omission of the primary antibody. The Vector ABC peroxidase substrate kit was then
used to visualize the antibody staining, and sections were lightly counterstained with
Hematoxylin, prior to mounting. Digital images were obtained at various magnifications
(25 to 200) on a Zeiss Axiovert 40CFL microscope using AxioVision Release 4.6.3
digital imaging software (Carl Zeiss MicroImaging, Inc. Thornwood, NY).

3.2.7. Mechanical Testing
For collagen scaffolds, a 12 mm x 12 mm square was cut from a central region of
the cusp, with one edge aligned along the circumferential direction and another edge
aligned along the radial direction (n = 5). Similarly, a 12 mm x 12 mm square specimen
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was cut from the arterial scaffolds, maintaining orientation of the circumferential and
longitudinal axes of the artery. The biaxial testing method has been reported previously27.
Briefly, four markers were placed in the center of the specimen to track tissue
deformation. A total of 8 loops of 000 polyester suture of equal length were attached to
the sample via stainless steel hooks, with two loops on each side of the square specimen.
Specimens were first preconditioned for 10 contiguous cycles, then loaded up to 60:60
N/m equibiaxial tension for collagen scaffolds and 20:20 N/m tension for elastin
scaffolds. Tissue extensibility was characterized by λcirc and λrad, the maximum stretch
ratio along the circumferential and radial directions, respectively. The biaxial testing was
implemented with the samples completely immersed in PBS (pH 7.4) at physiological
temperature (37°C).

3.2.8. Differential Scanning Calorimetry
To determine the thermal denaturation temperature (Td), also known as shrinkage
temperature, a well-known indicator of collagen crosslinking33, samples (n = 3) were
subjected to differential scanning calorimetry (DSC, model 131 Setaram Instrumentation,
Caluire, France) at a heating rate of 10°C/min from 20°C to 110°C in a N2 gas
environment. T2 was defined as the temperature at the endothermic peak.

3.2.9. Detection of AGEs and MDA
N-epsilon-(carboxymethyl)lysine (CML) was detected by IHC, (ABC kit, Vector
Laboratories). Briefly, rehydrated parrafin sections (5 mm, n = 4 per group) were exposed
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to 0.1% Proteinase K in 10 mM Tris buffer, pH 7.5, at room temperature for 30s to
unmask the antigens. Endogenous peroxidases were blocked with 0.3% hydrogen
peroxide in 0.3% horse normal serum. Sections were treated with 0.025% Triton X-100
for 10 min and then incubated with normal blocking serum for 20 min. Primary antibody
(4 mg/mL mouse anti-CML) was applied for 1h at room temperature. Rat-adsorbed
biotinylated anti-mouse IgG was used as a secondary antibody. Negative staining controls
were obtained by the omission of the primary antibody. The ABC peroxidase substrate kit
was then used to visualize the antibody staining, and sections were lightly counterstained
with hematoxylin before mounting.
To detect and measure pentosidine and MDA in explanted scaffolds, tissues were
weighed and their mass recorded. Samples were then incubated with collagenase type I
(100 U/sample) in 50 mM HEPES buffer with 10 mM CaCl2, pH = 7.5 at 37°C until fully
digested (2-4 days). Samples were then centrifuged for 10 min at 12000 rpm at 22°C and
the supernatant collected. Fluorescence of the supernatant was measured at 335/385 for
pentosidine and at 390/460 for MDA8 and expressed as relative fluorescence units per
milligram original tissue wet weight.

3.2.10. Evaluation of Infiltrated Cell Phenotype
In order to identify the cells infiltrated in the scaffolds, we used IHC (n = 4
samples per group), following the protocol described above for CML, and specific
antibodies for fibroblasts (vimentin), T-lymphocytes (CD8) and macrophages (CD68).
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3.2.11. MMP and TIMP Detection
MMPs were detected in explanted scaffolds as described before20. Briefly,
proteins were extracted by pulverizing liquid nitrogen-frozen tissue samples and
homogenizing them in RIPA extraction buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl,
1 mM EDTA, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS, with protease
inhibitor cocktail). Protein concentration was determined using BCA assay. For each
sample, 6 mg per lane were loaded, alongside pre-stained molecular weight standards.
After staining, the MMP clear bands on a dark background were evaluated by
densitometry on a FluorChem SP imager and the Alpha EaseFC Software v. 4.1.0 by
Alpha Innotech Corporation (Protein Simple, Santa Clara, CA) and expressed as relative
density units normalized to protein content. Tissue inhibitors of MMPs (TIMP) levels
were measured in the same protein extracts (n = 6 per group, all 6 pooled into one assay
sample) using a Rat Cytokine Array Panel (Proteome Profiler Antibody Array Panel A,
R&D Systems, Minneapolis, MN).

3.2.12. Calcium Analysis
Alizarin Red histology staining for calcium deposits was performed on sections of
explanted scaffolds (n = 4 per group) as described previously

34, 35

. Calcium content was

analyzed in tissue protein extracts (n = 4 per group, see above method for MMP analysis)
using a QuantiChrom Calcium Assay Kit (BioAssay Systems, Hayward, CA).
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3.2.13. Statistical Analysis
Results are expressed as means ± standard deviation (SD). Statistical analysis was
performed using one-way analysis of variance (ANOVA). Differences between means
were determined using the least significant difference (LSD) with an alpha (α) value of
0.05.

3.3. Results
3.3.1. Collagen and Elastin Scaffold Characterization
Initial studies focused on characterization of the two scaffolds before pursuing
implantation studies. Porcine aortic cusps and carotid arteries were chemically treated in
order to remove all cells, but preserve the ECM components (methods of
decellularization have been published by us previously)24,

25

. As seen in Fig. 3.1.1,

scaffolds showed complete elimination of cells (H&E staining); DNA analysis (agarose
gel electrophoresis followed by densitometry, PicoGreen quantitative DNA assay, and
Agilent Bioanalyzer lab-on-a-chip DNA kit) revealed complete DNA reduction after
decellularization treatment in both tissues (results not shown). The scaffold exhibited
typical “pores” (i.e. areas devoid of content where the original cells used to be), while
maintaining most of the original matrix proteins, as confirmed by Movat’s Pentachrome
staining. In the cusp scaffolds, collagen predominated and was well preserved. Intact
elastin fibers in the ventricularis layer were also visible. In the spongiosa layer, we
noticed the loss of glycosaminoglycans. In the arterial scaffolds, elastin sheets were well
preserved in all arterial tunics, while collagen was less visible (Fig. 3.1). IHC staining for
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Fig. 3.1.1. Macroscopic and histological images of fresh and decellularized (decell) porcine
aortic valve cusps (collagen scaffolds) and carotid arteries (elastin scaffolds) used in this study.
For histological analysis, tissues were stained with Hematoxylin and Eosin (H&E, dark purple =
nuclei, pink = background substance) and Movat’s Pentachrome (yellow = collagen, blue =
glycosaminoglycans, dark purple = elastin, bright red = nuclei). Tissues and scaffolds were also
stained by immunohistochemistry for laminin and collagen type IV (brown = positive). Cusp
layers: V = ventricularis, S = spongiosa, F = fibrosa. Arterial layers: I = intima, M = media, A =
adventitia.

Fig. 3.1.2. Graphs depicting average blood glucose level (left) and average weight (right) of both
control and diabetic rat models over course of study
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basal lamina components revealed good preservation of collagen type IV in both
scaffolds, while laminin showed only moderate retention in the cusp scaffolds.

3.3.2. Diabetes-related Scaffold Stiffening and Crosslinking
Biaxial tensile test analysis showed that collagen and elastin scaffolds implanted
in diabetic rats exhibited markedly increased stiffness in both radial and circumferential
directions compared to scaffolds implanted into control (non-diabetic) rats (Fig. 3.2).
Remarkably, PGG-treatment appeared to halt the pathological stiffening effect observed
in scaffolds implanted into diabetic rats. Thus, there were no statistical differences in
mechanical properties in either the radial or circumferential directions of PGG-treated
acellular cusps and arteries implanted in diabetic rats as compared to their controls.
Differential scanning calorimetry (DSC) showed significantly higher thermal
denaturation temperatures (Td) of scaffolds explanted from diabetic environments (Fig.
3.2), strongly suggesting that diabetes induced stiffening and crosslink formation in
collagen and elastin scaffolds.

3.3.3. Glycoxidation and Lipid Peroxidation
Having demonstrated that diabetes induced matrix protein crosslinking, we sought
to further define diabetes-related changes in scaffolds implanted subdermally in diabetic
rats. The presence of AGEs, specifically CML and pentosidine, and lipid peroxidation
products such as MDA were demonstrated in implanted scaffolds (Fig 3.3). Baseline
levels of CML were detected by IHC in all scaffolds, regardless of glycemic conditions.
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Fig. 3.2. Mechanical properties and matrix cross-linking in explanted scaffolds. Biaxial stress
strain analysis showing tension vs. stretch plots, and differential scanning calorimetry (DSC)
showing thermal denaturation temperatures (Td) of collagen scaffolds (top panel) and elastin
scaffolds (bottom panel) after subdermal implantation in control rats and in diabetic rats.
*Indicates statistical significance.
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Remarkably, CML antigen was highly expressed in non-PGG-treated scaffolds
implanted in diabetic conditions, and was associated with both infiltrated host cells and
the implanted extracellular matrix. However, PGG-treatment of the scaffolds before
implantation markedly decreased the accumulation of CML in diabetic environments,
particularly in the extracellular matrix (Fig. 3.3). Pentosidine and MDA detection in
scaffold extracts essentially confirmed IHC results, showing that PGG-treated scaffolds
allowed significantly less AGE formation and accumulation in diabetic environments
when compared to non- PGG-treated scaffolds (p > 0.001).

3.3.4. Cellular Infiltration
In order to learn how the diabetic host cells react to the implanted collagen and
elastin scaffolds and whether the treatment with PGG affects the inflammatory cell
infiltration, we analyzed the scaffolds by H&E staining and IHC four weeks after
implantation. H&E staining documented host cell infiltration permeating the scaffolds,
preferentially through the ventricularis layer in the cusp and the adventitia in the artery
(Figs. 3.4 and 3.5). Host cells appeared to have an affinity for the pore spaces in the
collagen scaffolds and spaces between elastin fibers. No differences were observed in cell
infiltration patterns between non-PGG-treated scaffolds implanted in diabetic rats as
compared to those implanted in control, non-diabetic rats. PGG-treatment of scaffolds
before implantation slightly reduced, but did not inhibit cellular infiltration.
IHC stain for vimentin documented an influx of fibroblasts into all scaffolds
regardless of glycemic environments. Fibroblasts were seen to migrate throughout the
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Fig. 3.3. Advanced glycation end products and lipid peroxidation products in explanted
scaffolds. (top panel) Immunohistochemical detection of carboxymethyl lysine (CML) in nontreated and PGG-treated collagen and elastin scaffolds implanted in control and diabetic rats
(positive 1⁄4 brown). (bottom panel) Pentosidine (left) and malondialdehyde (MDA, right)
content in non-treated and PGG-treated collagen and elastin scaffolds after implantation in
diabetic rats. *Indicates statistical significance.
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scaffolds unhindered, and cell spreading was clearly seen in most areas analyzed.
Treatment of scaffolds with PGG did not appear to inhibit fibroblast infiltration or
spreading (Figs. 3.4 and 3.5). IHC for CD8 showed presence of few T-cells in all
scaffolds, but they were constrained to the edges of the scaffolds. Diabetic environments
appeared to elicit a greater T-cell response in non-treated scaffolds compared with control
non-treated scaffolds. PGG-treatment of scaffolds appeared to discourage T-cell
infiltration, though it did not completely inhibit it. IHC staining for CD68 (a panmacrophage antibody) showed presence of macrophages in all scaffolds, indicating an
inflammatory response. This was noticeably more aggressive in diabetic non-treated
scaffolds (Figs. 3.4 and 3.5). An evident decrease in general macrophage presence was
observed in PGG-treated tissues, suggesting that PGG might discourage the macrophage
inflammatory response of the host to the scaffolds.

3.3.5. ECM Remodeling
Non-PGG-treated scaffold ECM integrity was slightly compromised after
implantation, with signs of matrix degradation visible in both collagen and elastin
scaffolds stained with Movat’s Pentachrome (Fig. 3.6). Conversely, treatment of
scaffolds with PGG before implantation preserved the structural integrity of the ECM in
both control and diabetic conditions. Collagen and elastin scaffolds were also analyzed
for MMP activities and amounts of TIMPs. Results showed higher MMP activities in
diabetic vs. non-diabetic rats and significantly reduced protease levels in PGG-treated
scaffolds. The highest reduction in MMP activity was noticed in PGG- treated scaffold
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Fig. 3.4. Cell infiltration in collagen scaffolds. Explants were stained by H&E and IHC (brown =
positive reaction)

Fig. 3.5. Cell infiltration in elastin scaffolds. Explants were stained by H&E and IHC (brown =
positive reaction)
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samples implanted in diabetic rats (Fig. 3.6). TIMP levels were highest in non-PGGtreated scaffolds implanted in control, non-diabetic rats (0.27 RDU per mg wet weight)
and lowest in PGG-treated scaffolds implanted in diabetic rats (0.19 RDU per mg wet
weight).

Fig. 3.6. ECM remodeling in implanted scaffolds. Scaffolds treated with PGG or non-treated
controls were implanted subdermally in control and diabetic rats. (upper panel) Explants were
stained with Movat’s Pentachrome histology stain (yellow = collagen, blue =
glycosaminoglycans, dark purple = elastin, bright red = nuclei). (bottom panel) Protein extracts
from collagen scaffolds (left) and elastin scaffolds (right) were analyzed for matrix
metalloproteinase activity by gelatin zymography followed by densitometry (inserts, positive =
white bands); results are shown as relative density units (RDU). *Indicates statistical significance.
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3.3.6. Calcification
To test for calcification, samples from all groups were stained with Alizarin Red
histological stain and also analyzed for calcium content using a colorimetric kit. Results
revealed no accumulation of calcium in any of the collagen scaffolds (baseline levels of
calcium) irrespective of glycemic status (Fig. 3.7). Elastin scaffolds however calcified
significantly after being implanted in both normal and diabetic rats (17 mg Ca/mg dry
weight) but did not accumulate any calcium deposits if pre-treated with PGG before
implantation (baseline levels, no red staining after Alizarin). These results point to
important structural differences between the two scaffolds and the outstanding effect of
PGG on prevention of elastin calcification.

Fig. 3.7. Calcification in implanted scaffolds. Scaffolds treated with PGG or non-treated controls
were implanted subdermally in control and diabetic rats. Explants were stained with Alizarin Red
histology stain for calcium (positive = red).
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3.4. Discussions
Biologic scaffolds composed of ECM proteins have been used in numerous
regenerative medicine applications, for both preclinical animal studies and clinical
purposes23, 36. The ECM is the natural 3D structure that assists the functions of cells and
tissues, not only providing structural support for cells, but also regulating processes such
as cell proliferation, survival, migration, and differentiation. Cell-matrix interactions
constantly determine the remodeling of ECM superstructures during the normal processes
of development and wound repair. However, when cells detect and respond to altered
matrix biochemical or mechanical stimuli from their environment, the dysfunctional
remodeling that might occur can contribute to the onset and progression of disease37. One
of the most daunting environments that could damage the ECM and its interaction with
cells is progressively built in diabetes. In the presence of high glucose concentrations,
long-lived ECM proteins such as collagen and elastin undergo irreversible crosslinking
by the formation of AGEs through non-enzymatic glycation (Maillard reaction). Reactive
oxygen species and free metal ions were identified as key participants in glycoxidation
and lipid peroxidation processes38. Furthermore, AGEs interact with specific receptors on
cell surfaces (RAGE), triggering continuous reactive oxygen species formation,
inflammation, and progressive vascular complications10. The consequences of severe
matrix alterations in diabetes are impaired healing, remodeling, and tissue regeneration,
all being key processes targeted in tissue engineering and regenerative medicine.
In studies presented here, we show that matrix-based scaffolds used for heart
valve and blood vessel tissue engineering accumulate AGEs, become crosslinked, change
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their mechanical and biochemical properties, trigger inflammatory reactions, and change
their matrix remodeling abilities when subjected to experimentally induced diabetes in
rats.
In order to prepare our collagen and elastin scaffolds, we developed suitable
methods that remove all cells, but do not disturb the overall scaffold architecture24, 25. Not
only did the major collagen and elastin components of the ECM maintain their structures,
but some basal lamina components, predominantly collagen type IV was also retained
post-decellularization. Several studies have shown that if the basal lamina is not
damaged, it provides a scaffold along which regenerating cells can migrate and
regenerate injured tissues such as muscle, nerves, and epithelia39-41. Since the
composition and architecture of the matrix are not compromised during decellularization,
our scaffolds have similar mechanical properties compared to fresh tissues. These results
are in agreement with several other studies that use decellularization methods, which do
not induce significant changes in the ECM composition vs. the native tissues and,
consequently, do not impair tissue strength28,

42

. However, when implanted

subcutaneously for four weeks in diabetic rats, both the collagen and the elastin scaffolds
showed significantly altered mechanical properties, becoming stiffer, compared to those
scaffolds implanted in non-diabetic surroundings. These physical changes are similar to
those already noticed in tissues obtained from diabetic patients. Without doubt, one of the
most prominent complications of hyperglycemia is associated with the alteration of the
vascular wall and, consequently, vascular stiffening is considered the hallmark of
diabetes43. There is much ongoing research examining the mechanical properties of large

	
  

72	
  

and peripheral arteries in diseased states44, 45, with particular emphasis on the aorta46.
However, there is currently little research examining mechanical properties of aortic
valve cusps in a pathological state such as diabetes, although aortic valve cusp thickening
and calcification were shown to be accelerated in diabetic patients, eventually ending in
heavily calcified, stiff cusps causing severe valve stenosis47, 48.
We noticed in our animal studies that the diabetic environment elicited a
pathological stiffening of collagen scaffolds, likely due to the crosslinking nature of
AGEs. DSC confirmed the crosslinked nature of the scaffolds by illustrating an increased
thermal denaturation temperature (Td) of 6-10°C, which can be considered significant. In
fact, in vitro studies have also reported the formation of AGEs by Fe

2+-

catalyzed, non-

enzymatic glycation7, 49, 50 of collagen type I incubated in vitro in solutions with high
glucose concentrations.
As diabetes is increasing to epidemic proportions worldwide with severe
consequences, numerous studies were performed to elucidate the nature of AGEs, their
involvement in the generation of permanent crosslinks of extracellular matrix proteins, as
well as their association with diabetes-induced complications. Concurrently, numerous
studies are focused on finding effective means of attenuating the glucose adduct
formation and the damage they are bringing to proteins38. Several strategies and agents
were considered such as aspirin, glutathione, and dibasic amino acids (lysine and
arginine) to block glucose adduct formation: amino- guanidine and pyridoxamine51, to
trap the sugar fragmentation products; N-phenacylthiazolum bromide, to break AGEs;
vitamin E and selenium, as agents with antioxidant supplements because the antioxidant
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defense system is perturbed in diabetes. As alterations in iron and copper homeostasis are
a characteristic feature of diabetes, chelators, such as triethylenetetramine or citrate, may
inhibit AGE formation51.
A number of publications report on the protection against diabetic complications
by several plant extracts, such as polyphenols, rutin52, and resveratrol. It is possible that
they may work in part by limiting the uptake or promoting the excretion of metal ions
through chelating activities51. Given that high levels of CML, pentosidine and MDA were
noticed in the collagen and elastin scaffolds exposed to the harmful environment in
diabetic rats (Figs. 3.2 and 3.3), we treated our scaffolds with PGG, a polyphenolic,
antioxidant stabilizing agent with high affinity for proline-rich proteins53, and implanted
them in diabetic rats. The reduced quantities of CML, pentosidine, and MDA in
implanted PGG-treated collagen scaffolds compared to non-treated scaffolds suggest that
PGG might protect cardiovascular tissue engineering scaffolds from diabetic
complications.
It is known that inflammatory cells are often present in altered diabetic tissues54
Neutrophil, macrophage, and T-cell accumulation was also noticed in the collagen and
elastin-based scaffolds implanted in diabetic rats. However, in the PGG-treated scaffolds,
we noticed less cell infiltration. As there is a highly regulated connection between AGEs,
oxidative stress, and inflammation, it is possible that the antioxidant nature of PGG is
halting the glycoxidation, which in turn, ceases the further acceleration of AGE
accumulation and inflammation. These results are in agreement with other papers that
describe PGG as an anti-inflammatory and anti-oxidative agent 55.
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PGG was also efficient in preventing calcium accumulation in the elastin
scaffolds. Many studies have demonstrated that elastin calcification is a widespread
feature of vascular pathology35, 56, 57 and that the glycoxidative modification of elastin is a
potential accelerating factor for diabetic macroangiopathy58,

59

. In our studies, the

acellular elastin scaffolds exhibited massive calcium deposits in the media after
implantation in both control and diabetic rats. Auspiciously, the PGG-treated elastin
scaffolds revealed no detectable calcium accumulation in vivo. These results were in
agreement with studies done by Chuang et al., who showed that there were no detectable
deposits of calcium salts at four weeks after subcutaneous implantation in normal rats24.
In this study, we show that PGG is able to prevent calcification of elastin scaffolds in
diabetic rats as well. Similarly, it was demonstrated earlier that tannic acid (a chemical
derivative of PGG) decreased calcification of glutaraldehyde treated aorta implanted in
the rat subdermal model60. The same authors revealed that stabilization of abdominal
aorta with PGG reduced the onset and progression of abdominal aorta aneurysms and that
PGG-treated aortas exhibited improved preservation of elastic laminar integrity,
waviness, and overall preserved tissue architecture in a well- established abdominal aortic
aneurysm model in rats34.
On the other hand, our collagen scaffolds were not readily susceptible to
calcification upon four weeks implantation in diabetic rats, although studies have shown
that diabetes is a strong predictor for aortic valve calcification61. The acellular collagen
scaffolds proved to be resistant to calcification, possibly as a result of the mild detergentbased method that we used to decellularize the tissue (it has been shown that degraded
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collagen fibers are associated with valve calcification)62,

63

. In addition, PGG might

prevent the further disorganization of matrix components, reducing the infiltration of
inflammatory cells and the synthesis of matrix proteases, which play a significant role in
elastin and collagen calcification35. The activity of MMPs was slightly higher in scaffolds
implanted in diabetic rats, compared to non-diabetic rats; as expected, TIMP levels were
lower in diabetic conditions. These results are in agreement with studies that show that
both MMP activities and TIMP protein levels are altered in different cell types isolated
from diabetic patients11. In our scaffolds, MMP levels were about 50% lower in PGGtreated scaffolds implanted in both non-diabetic and diabetic rats. This indicates that the
remodeling process would be likely decelerated, allowing prolonged scaffold retention,
an essential characteristic for use in replacement of cardiovascular tissues.

3.5. Conclusions
Collagen and elastin-based scaffolds used for heart valve and blood vessel tissue
engineering accumulate AGEs, become stiffer, and change their matrix remodeling
abilities when subjected to experimentally induced diabetes in rats. Pre-implantation
treatment of scaffolds with PGG, an antioxidant matrix-binding polyphenol, stabilizes the
scaffolds and protects them from diabetes-related complications thereby supporting their
future use for cardiovascular tissue engineering in diabetic patients.

3.6. References
1. Goldberg RB. Cardiovascular disease in patients who have diabetes. Cardiology
clinics. 2003;21:399-413, vii.

	
  

76	
  

2. Briand M, Lemieux I, Dumesnil JG, Mathieu P, Cartier A, Despres JP, Arsenault
M, Couet J and Pibarot P. Metabolic syndrome negatively influences disease
progression and prognosis in aortic stenosis. Journal of the American College of
Cardiology. 2006;47:2229-36.
3. Messika-Zeitoun D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Nkomo VT,
Breen JF, Maalouf J, Scott C, Tajik AJ and Enriquez-Sarano M. Aortic Valve
Calcification: Determinants and Progression in the Population. Arteriosclerosis,
Thrombosis, and Vascular Biology. 2007;27:642-648.
4. Peterson LR, McKenzie CR and Schaffer JE. Diabetic Cardiovascular Disease:
Getting to the Heart of the Matter. Journal of Cardiovascular Translational
Research. 2012;5:436-445.
5. Sakata N. Modification of elastin by pentosidine is associated with the
calcification of aortic media in patients with end-stage renal disease. Nephrology
Dialysis Transplantation. 2003;18:1601-1609.
6. Winlove CP, Parker KH, Avery NC and Bailey AJ. Interactions of elastin and
aorta with sugars in vitro and their effects on biochemical and physical properties.
Diabetologia. 1996;39:1131-9.
7. Meli M, Granouillet R, Reynaud E, Chamson A, Frey J and Perier C. In vitro
glycoxidation of insoluble fibrous type I collagen: solubilization and advanced
glycation end products. Journal of protein chemistry. 2003;22:527-31.
8. Sakuda S, Tamura S, Yamada A, Miyagawa J, Yamamoto K, Kiso S, Ito N,
Higashiyama S, Taniguchi N, Kawata S and Matsuzawa Y. NF-kappaB activation
in non-parenchymal liver cells after partial hepatectomy in rats: possible
involvement in expression of heparin-binding epidermal growth factor-like
growth factor. Journal of hepatology. 2002;36:527-33.
9. Nagai R, Murray DB, Metz TO and Baynes JW. Chelation: a fundamental
mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of
diabetes complications. Diabetes. 2012;61:549-59.
10. Negre-Salvayre A, Salvayre R, Auge N, Pamplona R and Portero-Otin M.
Hyperglycemia and Glycation in Diabetic Complications. Antioxidants & Redox
Signaling. 2009;11:3071-3109.
11. Tayebjee MH, Lip GYH and MacFadyen RJ. What role do extracellular matrix
changes contribute to the cardiovascular disease burden of diabetes mellitus?
Diabetic Medicine. 2005;22:1628-1635.
12. Huebschmann AG. Diabetes and Advanced Glycoxidation End Products.
Diabetes Care. 2006;29:1420-1432.
13. Nguyen LL. Percutaneous treatment of peripheral vascular disease: the role of
diabetes and inflammation. J Vasc Surg. 2007;45 Suppl A:A149-57.
14. Nugent HM. Tissue Engineering Therapy for Cardiovascular Disease. Circulation
research. 2003;92:1068-1078.
15. Mensah GA, Catravas JD, Engelgau MM, Hooper WC, Madeddu P, Ryan US,
She J-X, Reed E, Vinicor F and Yacoub MH. Vascular endothelium summary
statement VI: Research directions for the 21st century☆. Vascular
Pharmacology. 2007;46:330-332.

	
  

77	
  

16. Krawiec JT and Vorp DA. Adult stem cell-based tissue engineered blood vessels:
a review. Biomaterials. 2012;33:3388-400.
17. Peck M, Gebhart D, Dusserre N, McAllister TN and L'Heureux N. The evolution
of vascular tissue engineering and current state of the art. Cells, tissues, organs.
2012;195:144-58.
18. Isenberg BC, Williams C and Tranquillo RT. Small-diameter artificial arteries
engineered in vitro. Circulation research. 2006;98:25-35.
19. Schoen FJ. Cardiac valves and valvular pathology - Update on function, disease,
repair, and replacement. Cardiovascular Pathology. 2005;14:189-194.
20. Tedder ME, Liao J, Weed B, Stabler C, Zhang H, Simionescu A and Simionescu
DT. Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering. Tissue
Engineering Part A. 2009;15:1257-1268.
21. Iyer RK, Chiu LL, Reis LA and Radisic M. Engineered cardiac tissues. Current
opinion in biotechnology. 2011;22:706-14.
22. Bursac N, Papadaki M, White JA, Eisenberg SR, Vunjak-Novakovic G and Freed
LE. Cultivation in rotating bioreactors promotes maintenance of cardiac myocyte
electrophysiology and molecular properties. Tissue engineering. 2003;9:1243-53.
23. Badylak SF. The extracellular matrix as a biologic scaffold material.
Biomaterials. 2007;28:3587-3593.
24. Chuang TH, Stabler C, Simionescu A and Simionescu DT. Polyphenol-Stabilized
Tubular Elastin Scaffolds for Tissue Engineered Vascular Grafts. Tissue
Engineering Part A. 2009;15:2837-2851.
25. Sierad L, Simionescu A, Albers C, Chen J, Maivelett J, Tedder M, Liao J and
Simionescu D. Design and Testing of a Pulsatile Conditioning System for
Dynamic Endothelialization of Polyphenol-Stabilized Tissue Engineered Heart
Valves. Cardiovascular engineering and technology. 2010;1:138-153.
26. Barnes CA, Brison J, Michel R, Brown BN, Castner DG, Badylak SF and Ratner
BD. The surface molecular functionality of decellularized extracellular matrices.
Biomaterials. 2011;32:137-143.
27. Liao J, Joyce EM and Sacks MS. Effects of decellularization on the mechanical
and structural properties of the porcine aortic valve leaflet. Biomaterials.
2008;29:1065-1074.
28. Dahan N, Zarbiv G, Sarig U, Karram T, Hoffman A and Machluf M. Porcine
small diameter arterial extracellular matrix supports endothelium formation and
media remodeling forming a promising vascular engineered biograft. Tissue
engineering Part A. 2012;18:411-22.
29. Cummings I, George S, Kelm J, Schmidt D, Emmert MY, Weber B, Zund G and
Hoerstrup SP. Tissue-engineered vascular graft remodeling in a growing lamb
model: expression of matrix metalloproteinases. European journal of cardiothoracic surgery : official journal of the European Association for Cardiothoracic Surgery. 2012;41:167-72.
30. Henriksen EJ, Diamond-Stanic MK and Marchionne EM. Oxidative stress and the
etiology of insulin resistance and type 2 diabetes. Free radical biology &
medicine. 2011;51:993-9.

	
  

78	
  

31. Rees DA and Alcolado JC. Animal models of diabetes mellitus. Diabetic
medicine : a journal of the British Diabetic Association. 2005;22:359-70.
32. Styskal J, Van Remmen H, Richardson A and Salmon AB. Oxidative stress and
diabetes: what can we learn about insulin resistance from antioxidant mutant
mouse models? Free radical biology & medicine. 2012;52:46-58.
33. Kasyanov V, Isenburg J, Draughn RA, Hazard S, Hodde J, Ozolanta I, Murovska
M, Halkes SB, Vrasidas I, Liskamp RM, Pieters RJ, Simionescu D, Markwald RR
and Mironov V. Tannic acid mimicking dendrimers as small intestine submucosa
stabilizing nanomordants. Biomaterials. 2006;27:745-51.
34. Isenburg JC, Simionescu DT, Starcher BC and Vyavahare NR. Elastin
stabilization for treatment of abdominal aortic aneurysms. Circulation.
2007;115:1729-1737.
35. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC and Vyavahare
NR. Elastin degradation and calcification in an abdominal aorta injury model: role
of matrix metalloproteinases. Circulation. 2004;110:3480-7.
36. Badylak SF, Freytes DO and Gilbert TW. Extracellular matrix as a biological
scaffold material: Structure and function. Acta biomaterialia. 2009;5:1-13.
37. Daley WP, Peters SB and Larsen M. Extracellular matrix dynamics in
development and regenerative medicine. Journal of cell science. 2008;121:25564.
38. Reiser KM. Nonenzymatic glycation of collagen in aging and diabetes.
Proceedings of the Society for Experimental Biology and Medicine Society for
Experimental Biology and Medicine (New York, NY). 1991;196:17-29.
39. Chen X and Li Y. Role of matrix metalloproteinases in skeletal muscle:
migration, differentiation, regeneration and fibrosis. Cell adhesion & migration.
2009;3:337-41.
40. La Fleur M, Underwood JL, Rappolee DA and Werb Z. Basement membrane and
repair of injury to peripheral nerve: defining a potential role for macrophages,
matrix metalloproteinases, and tissue inhibitor of metalloproteinases-1. The
Journal of experimental medicine. 1996;184:2311-26.
41. Albera C, Polak JM, Janes S, Griffiths MJ, Alison MR, Wright NA,
Navaratnarasah S, Poulsom R, Jeffery R, Fisher C, Burke M and Bishop AE.
Repopulation of human pulmonary epithelium by bone marrow cells: a potential
means to promote repair. Tissue engineering. 2005;11:1115-21.
42. Korossis SA, Wilcox HE, Watterson KG, Kearney JN, Ingham E and Fisher J. Invitro assessment of the functional performance of the decellularized intact porcine
aortic root. The Journal of heart valve disease. 2005;14:408-21; discussion 422.
43. Martens FM, van der Graaf Y, Dijk JM, Olijhoek JK and Visseren FL. Carotid
arterial stiffness is marginally higher in the metabolic syndrome and markedly
higher in type 2 diabetes mellitus in patients with manifestations of arterial
disease. Atherosclerosis. 2008;197:646-53.
44. Soldatos G, Jandeleit-Dahm K, Thomson H, Formosa M, D'Orsa K, Calkin AC,
Cooper ME, Ahimastos AA and Kingwell BA. Large artery biomechanics and

	
  

79	
  

diastolic dysfunctionin patients with Type 2 diabetes. Diabetic Medicine.
2011;28:54-60.
45. Webb DR, Khunti K, Silverman R, Gray LJ, Srinivasan B, Lacy PS, Williams B
and Davies MJ. Impact of metabolic indices on central artery stiffness:
independent association of insulin resistance and glucose with aortic pulse wave
velocity. Diabetologia. 2010;53:1190-1198.
46. Karamitsos TD, Karvounis HI, Didangellos TP, Papadopoulos CE, Dalamanga
EG, Karamitsos DT, Parharidis GE and Louridas GE. Usefulness of colour tissue
Doppler imaging in assessing aortic elastic properties in Type 1 diabetic patients.
Diabetic Medicine. 2006;23:1201-1206.
47. Rosenhek R and Baumgartner H. Aortic sclerosis, aortic stenosis and lipidlowering therapy. Expert review of cardiovascular therapy. 2008;6:385-90.
48. Falcao-Pires I, Hamdani N, Borbely A, Gavina C, Schalkwijk CG, van der Velden
J, van Heerebeek L, Stienen GJ, Niessen HW, Leite-Moreira AF and Paulus WJ.
Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis
through altered myocardial structure and cardiomyocyte stiffness. Circulation.
2011;124:1151-9.
49. Xiao H, Cai G and Liu M. Fe2+-catalyzed non-enzymatic glycosylation alters
collagen conformation during AGE-collagen formation in vitro. Archives of
biochemistry and biophysics. 2007;468:183-192.
50. Meli M, Granouillet OR, Reynaud E, Chamson l A, Frey J and Perier C. Changes
in glycation of fibrous type I collagen during long-term in vitro incubation with
glucose. Journal of protein chemistry. 2003;22:521-5.
51. Alt N, Carson JA, Alderson NL, Wang Y, Nagai R, Henle T, Thorpe SR and
Baynes JW. Chemical modification of muscle protein in diabetes. Arch Biochem
Biophys. 2004;425:200-6.
52. Cervantes-Laurean D, Schramm DD, Jacobson EL, Halaweish I, Bruckner GG
and Boissonneault GA. Inhibition of advanced glycation end product formation
on collagen by rutin and its metabolites. Journal of Nutritional Biochemistry.
2006;17:531-540.
53. Charlton AJ, Baxter NJ, Lilley TH, Haslam E, McDonald CJ and Williamson MP.
Tannin interactions with a full-length human salivary proline-rich protein display
a stronger affinity than with single proline-rich repeats. Febs Letters.
1996;382:289-292.
54. Galkina E and Ley K. Leukocyte recruitment and vascular injury in diabetic
nephropathy. Journal of the American Society of Nephrology. 2006;17:368-377.
55. Zhang JH, Li L, Kim SH, Hagerman AE and Lu JX. Anti-Cancer, Anti-Diabetic
and Other Pharmacologic and Biological Activities of Penta-Galloyl-Glucose.
Pharmaceutical Research. 2009;26:2066-2080.
56. Sage AP, Tintut Y and Demer LL. Regulatory mechanisms in vascular
calcification. Nature reviews Cardiology. 2010;7:528-36.
57. Bostrom KI, Rajamannan NM and Towler DA. The regulation of valvular and
vascular sclerosis by osteogenic morphogens. Circulation research.
2011;109:564-77.

	
  

80	
  

58. Edmonds ME. Medial arterial calcification and diabetes mellitus. Zeitschrift fur
Kardiologie. 2000;89 Suppl 2:101-4.
59. Lehto S, Niskanen L, Suhonen M, Ronnemaa T and Laakso M. Medial artery
calcification - A neglected harbinger of cardiovascular complications in noninsulin-dependent diabetes mellitus. Arteriosclerosis Thrombosis and Vascular
Biology. 1996;16:978-983.
60. Isenburg JC, Simionescu DT and Vyavahare NR. Tannic acid treatment enhances
biostability and reduces calcification of glutaraldehyde fixed aortic wall.
Biomaterials. 2005;26:1237-45.
61. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM, Probstfield JL, Bertoni
AG, Budoff MJ and O'Brien KD. Features of the metabolic syndrome and
diabetes mellitus as predictors of aortic valve calcification in the multi-ethnic
study of atherosclerosis. Circulation. 2006;113:2113-2119.
62. Gu X and Masters KS. Regulation of valvular interstitial cell calcification by
adhesive peptide sequences. Journal of biomedical materials research Part A.
2010;93:1620-30.
63. Simionescu A, Schulte JB, Fercana G and Simionescu DT. Inflammation in
cardiovascular tissue engineering: the challenge to a promise: a minireview.
International journal of inflammation. 2011;2011:958247.
	
  

	
  

81	
  

CHAPTER 4: EVALUATION OF AUTOLOGOUS ADIPOSE STEM CELL
REVITALIZATION ON SCAFFOLDS IN DIABETES
(This work has been submitted to Biomaterials)
4.1. Introduction
Diabetes is a well-known major risk factor for the progression of cardiovascular
disease 1-5. More alarming, the prevalence of diabetes is globally on the rise, expected to
increase from 366 million people in 2011 to 552 million by 20306. The central
mechanism driving vascular complications in diabetes is chronic inflammation.
Hyperglycemia and dyslipidemia induce activation of the endothelium and modifications
of matrix components, both changes resulting in inflammation. The formation of
advanced glycation end products (AGEs) and their interaction with RAGE, their specific
cell surface receptor, stimulate the formation of reactive oxygen species (ROS), which,
together with dysfunctions of mitochondria, contribute to the oxidative stress in diabetes;
indeed, superoxide generation is believed to accelerate the pathogenesis of cardiovascular
diseases in diabetes7-11. Furthermore, increased ROS production positively correlates with
activation of innate immunity

12

and, subsequently,

monocytes and macrophages

infiltrate in diabetic aorta13. In addition, the pro inflammatory state of diabetes has been
recognized for its pro-calcific potential14, 15. Elevated levels and faster progression of
arterial calcification are consistently reported in populations with diabetes16. Vascular
calcification can occur in either the intima, caused by atherosclerosis, or the media of the
vessel wall, more associated with diabetic conditions17.
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Tissue engineering is rapidly emerging as a potential solution for the treatment of
vascular diseases18,

19

; however, there is a gap in the understanding of how tissue

engineered vascular products will perform when implanted in patients with diabetes. We
have previously reported on the grim fate of collagen and elastin scaffolds used for
cardiovascular tissue engineering which might ultimately lead to their failure after
implantation into a diabetic environment20. Surely, the observed matrix stiffening, the
elevated state of inflammation and calcification are not conducive to graft integration and
vascular tissue regeneration. We suggested previously a treatment for the scaffolds with
penta-galloyl glucose (PGG), a matrix-binding polyphenol with intrinsic antioxidant
properties, which protected the matrix from pathological diabetes-induced adverse
reactions.
Scaffolds, however, are just one key ingredient in the tissue-engineering
paradigm; they must be seeded with cells in order to promote new tissue generation and
remodeling, leading to construct integration21,

22

.

Adipose tissue-derived stem cells

(ASCs) have recently been identified as a promising stem cell source due to their
immunomodulatory properties, ability to differentiate into various vascular cells and their
availability

23-26

. Stem cell immunomodulation, in particular, holds high potential for

tissue engineered construct integration by reducing inflammatory cytokine production,
suppressing cytotoxic T-cell proliferation, and stimulating the secretion of antiinflammatory cytokines such as IL-4 and IL-1026-29. Furthermore, ASCs have been
shown to regulate macrophage polarization by reduction of classically activated pro
inflammatory M1 macrophage phenotype in favor of the alternatively activated pro
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healing M2 macrophage phenotype30-32. M1 macrophages are responsible for chronic
inflammation, secreting abundant amounts of IL-6, TNF-α, as well as toxic reactive
oxygen intermediates and nitric oxide, generated by activated iNOS 33, 34.
Suppression of chronic inflammation is key for tissue engineered construct
survival and integration. However, the ability of ASCs to moderate the aggressive
inflammatory environment that diabetes elicits in response to tissue-engineered implants
has not been explored. Hence, we hypothesize that the immunosuppressive capabilities of
autologous ASCs seeded on vascular scaffolds would temperate the diabetes-intensified
inflammatory reactions. Furthermore, the combined effect of immunomodulatory ASCs
and antioxidant PGG would inhibit calcification and positively impact remodeling of
tissue-engineered vascular constructs when implanted subcutaneously in diabetic rats.

4.2. Materials and Methods
4.2.1. Materials
High-purity penta-galloyl glucose was a generous gift from N.V. Ajinomoto
OmniChem S.A., Wetteren, Belgium (www.omnichem.be). Streptozotocin was from
Sigma (S0130). The insulin preparation used for rats in this study was Humulin N U-100
NPH, Human Insulin of rDNA origin isophane suspension from Lilly (Indianapolis, IN).
AlphaTRAK (Gen II) test strip and the AlphaTRAK Blood Glucose Monitoring System
was from Abbott Laboratories, Animal Health (Abbott Park, IL). Electrophoresis
apparatus, chemicals, and molecular weight standards were from Bio-Rad (Hercules,
CA). Bicinchoninic acid protein assay kit was from Pierce Biotech (Rockford, IL). The
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VECTASTAIN Elite ABC reagent, R.T.U. (#PK-7100) and the diaminobenzidine
tetrahydrochloride (DAB) peroxidase substrate kit (#SK-4100) were purchased from
Vector Laboratories (Burlingame, CA). We used the following antibodies: rabbit antilaminin (ab11575, Abcam), monoclonal anti-vimentin (V5255, Sigma), mouse anti-CD8
(GTX76218, GeneTex Inc, Irvine, CA), mouse anti-CD68 (ab31630, Abcam), rabbit antiiNOS (ab15323, Abcam), rabbit anti-CCR7 (CG1678, Cell Applications Inc, San Diego,
CA), mouse anti-CD163 (ab111250, Abcam), rabbit anti-osteopontin (ab8448, Abcam),
rabbit anti-alkaline phosphatase (ab108337, Abcam), rabbit anti-RAGE (ab37647,
Abcam), sheep anti-CD34 (AF6518, R&D Systems, Minneapolis, MN), and rabbit antialpha-smooth muscle actin (ab5694, Abcam). We used to following ELISA kits: TNF-α
Rat ELISA Kit (ab100785, Abcam) and Prostaglandin E2 Express EIA Kit (#500141,
Cayman Chemical, San Antonio, TX). Alizarin Red 1% aqueous staining solution was
obtained from Poly Scientific R&D Corp (#s2007, Bay Shore, NY). All other chemicals
were of highest purity available and were obtained from Sigma Aldrich Corporation
(Lakewood, NJ).

4.2.2. Arterial Elastin Scaffold Preparation
Elastin scaffolds were prepared following an alkaline extraction protocol
described before, with minor modifications [25]. Briefly, fresh porcine carotid arteries (68 cm long, 5-6mm diameter) obtained from Animal Technologies, Inc. (Tyler, TX) were
rendered acellular by incubation in 0.1M NaOH solution at 37°C for 24 h followed by
extensive rinsing with deionized water until pH dropped to neutral. Scaffolds were stored
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in sterile PBS. This treatment removed all cells and most of the collagen, leaving vascular
elastin intact. Scaffolds were also completely devoid of the α-Gal epitope (data not
shown).

4.2.3. PGG Treatment
Acellular scaffolds were treated with sterile 0.1% PGG in 50mM 4-(2hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 5.5, containing 20%
isopropanol, overnight at room temperature under agitation and protected from light.
Scaffolds were then rinsed in sterile PBS and stored in sterile PBS containing 1%
protease inhibitor and 1% Pen-Strep at 4°C. The efficiency of PGG binding and tissue
stabilization was assessed previously by testing tissue resistance to collagenase and
elastase digestion [25,26]. Untreated scaffolds were used as controls.

4.2.4. Rat Model of STZ-induced Diabetes
Adult male Sprague Dawley rats (n = 40, weight 300-350 g) were rendered
diabetic via a single dose of sterile filtered 55 mg/kg streptozotocin solution in 0.1M
citrate buffer (pH 5) by tail vein injection. Control rats (n = 20) received an equal volume
of vehicle (sterile citrate buffer). Starting on day 3, levels of blood glucose were
determined 3-4 times per week, using AlphaTRAK (Gen II) test strips on the
AlphaTRAK Blood Glucose Monitoring System, designed specifically for animals.
Diabetes was established (>400 mg glucose/dL blood), and diabetic rats were given
subcutaneous injections of long-lasting insulin (2-4U Isophane) every other day to

	
  

86	
  

maintain blood glucose level in a desirable range (400-600 mg glucose/dL blood) and
prevent development of ketonuria and weight loss. Glucose levels, individual weights,
hydration status, and food and water consumption were monitored closely and
continuously graphed to ensure adequate health parameters. Animals were provided with
food and water ad libitum and were cared for by the attending university veterinarian and
associated staff at the Godley-Snell Research Center animal facility. The Animal
Research Committee at Clemson University approved the animal protocol, and National
Institute of Health (NIH) guidelines for the care and use of laboratory animals (NIH
publication #86-23 Rev. 1996) were observed throughout the experiment.

4.2.5. Adipose Stem Cell Isolation and Injection Into Scaffolds
A small amount of subcutaneous belly fat (~30mg) was harvested from each rat 2
weeks after STZ administration via lipectomy procedure and immediately processed
according to the Zuk procedure35. Briefly, adipose tissue was minced, washed with
ammonium chloride to remove red blood cells, incubated in collagenase, and centrifuged.
The stromal vascular fraction pellet was plated in tissue culture flasks and cultured for 2
weeks to propagate the adipose stem cells (ASCs). ASCs were then seeded into each
elastin scaffold at approximately 1X106 cells per scaffold (~5X104 cells per cm2) via
injection with 30G syringe at multiple sites along the scaffold. Recellularized scaffolds
were maintained in culture media overnight prior to subcutaneous implantation.
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4.2.6. Subdermal Implantation of Elastin Scaffolds
Four weeks after STZ administration, rats were prepped for surgery and
anesthetized using 1-2% isoflurane. Diabetic rats were given 1U of insulin preoperatively. A small, transverse incision was made on the back of the rats, and two
subdermal pouches were created by blunt dissection. Elastin scaffolds were cut open
longitudinally and 2-3 cm samples were implanted subdermally into each pouch (n=2
scaffolds per rat). Constructs with injected autologous ASC were also implanted into
each respective rat. The rats were allowed to recover, provided with food and water ad
libitum, and were cared for by the attending veterinarian and associated staff at the
Godley-Snell Research Center animal facility. Post-operative levels of blood glucose
were determined 3-4 times per week, and diabetic rats were given insulin as described
above. After four weeks, the rats were humanely euthanized by CO2 asphyxiation, and
the scaffolds were explanted and collected according to their respective assay application
as follows: scaffolds for histological analysis were placed in Karnovksy’s Fixative and
paraffin embedded, while samples for protein analysis were flash frozen in liquid
nitrogen and transferred to -20°C for storage.

4.2.7. Experimental Implant Groups
Scaffolds were divided into four groups as follows: a) non-treated elastin
scaffolds without ASCs; b) PGG-treated elastin scaffolds without ASCs; c) non-treated
elastin scaffolds with ASCs; d) PGG-treated elastin scaffolds with ASCs. Samples from
each group were implanted subdermally into control and diabetic rats (n = 20 implants
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per group) as detailed below.

4.2.8. Histology and Immunohistochemistry (IHC)
Paraffin-embedded scaffolds sections (5µm) were rehydrated and stained with
hematoxylin and eosin (Richard-Allen Scientific, Thermo Scientific) for a general
overview of scaffold integrity and to confirm presence of ASCs. For IHC, heat-mediated
antigen retrieval was implemented by immersing sections in 95-100°C solution of 10mM
citrate buffer (pH 6.0) for 20 min. Sections were then treated with 0.025% Triton X-100
for 10 min and blocked in 1.5% normal horse serum for 30min. Endogenous peroxidases
were blocked with 0.3% hydrogen peroxide in 0.3% horse normal serum for 30 min then
primary antibody was applied for 1 hr at room temperature, followed by incubation in
appropriate biotinylated secondary antibody (1:200 dilution, Vector Labs) for 30 min.
VECTASTAIN Elite ABC Reagent, R.T.U. was applied, and the chromogen was
visualized using the DAB Peroxidase Substrate Kit. Negative staining controls were
obtained by the omission of the primary antibody. Sections were lightly counterstained
with hematoxylin, prior to mounting. Digital images were obtained at various
magnifications (25X to 200X) on a Zeiss Axiovert 40CFL microscope using AxioVision
Release 4.6.3 digital imaging software (Carl Zeiss MicroImaging, Inc. Thornwood, NY).
We used the following antibody dilutions and concentrations: CD34 (1:200), CD68
(1:100), iNOS (1:100), CD163 (4µg/mL) CD8 (4µg/mL), vimentin (1:250), α-smooth
muscle actin (1:200) and laminin (1:25).

	
  

89	
  

4.2.9. Calcium and Bone Protein Analysis
Alizarin Red histology staining for calcium deposits was performed on sections of
explanted elastin scaffolds (n = 5 per group). Osteogenic markers, osteopontin (1:250
dilution) and alkaline phosphatase (1:300 dilution), were determined in elastin scaffolds
via IHC.

4.2.10. IHC Quantification
Relative quantification for immunohistochemistry stains was performed on
ImageJ (provided by NIH) using the ImmunoRatio plugin (Touminen and Isola,
University of Tampere, Finland). Quantities are expressed as a percentage of DAB to
nuclear area or ECM area, depending on stain type (cellular stain vs. matrix stain). Each
image was adjusted individually for brown threshold and blue threshold to fine-tune each
component. Proper instructions for use provided by the developer was followed.

4.2.11. Mechanical Testing
A 12mm x 12mm square specimen was cut from the elastin scaffolds, maintaining
orientation of the circumferential and longitudinal axes of the artery (n=5 per group). The
biaxial testing method has been reported previously [40]. Briefly, four markers were
placed in the center of the specimen to track tissue deformation. A total of 8 loops of 000
polyester suture of equal length were attached to the sample via stainless steel hooks,
with two loops on each side of the square specimen. Specimens were first preconditioned
for 10 contiguous cycles, and then loaded up 20:20 N/m tension for elastin scaffolds.
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Tissue extensibility was characterized by λcirc and λrad, the maximum stretch ratio along
the circumferential and radial directions, respectively. The biaxial testing was
implemented with the samples completely immersed in PBS (pH 7.4) at physiologic
temperature (37°C).

4.3. Results
4.3.1. In Vitro and In Vivo Imaging of ASCs Seeded Into Scaffolds
ASCs were injected into the scaffolds (~5X104 cells per cm2) and incubated
overnight in cell culture media. To confirm the presence of cells in the scaffolds before
implantation, three pieces were prepared for histology and analyzed by H&E and IHC for
CD34. Positive IHC staining for CD34 confirms presence of ASCs in the elastin scaffold
(Fig. 4.1C). Compared to unseeded scaffolds (Fig. 4.1A), the seeded samples showed
cell alignment along the elastin fibers (Fig.1B) that stained positive for CD34 (Fig.
4.1C). Cells prepared for injecting into six scaffolds were tagged with CFDA-SE and
then seeded. The fluorescently tagged cells could be imaged via IVIS before seeding
(Fig. 4.1 D), and monitored for up to two weeks post-implantation (Fig. 4.1 E and F).
After four weeks, however, the fluorescence of the tagged ASCs could not be detected.

4.3.2. ASCs Impact on Inflammatory Cell Infiltration
In order to evaluate the effect of implanted autologous ASC on the host reaction,
2 separate ASC-seeded scaffolds were implanted in each diabetic and non-diabetic rat for
four weeks; the types of infiltrated inflammatory cells were analyzed and compared to
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Figure 4.1. Histological images of (A) a decellularized elastin scaffold stained with H&E, (B)
ASC-recelluarized elastin scaffolds stained with H&E, and (B) CD34+ stain for ASCs via
immunohistochemistry (brown = positive). (D) Fluorescently tagged ASCs prior to elastin
scaffold recellularization. (E) IVIS image showing fluorescently labeled constructs after
subcutaneous implantation. (F) IVIS image of a rat with no implant as a negative control.
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acellular scaffolds implanted in non-diabetic and diabetic rats as well. The explants were
prepared for histology and sections were stained for T cells and macrophages. Elevated
levels of CD8+ T-cells (29.3%) and CD68+ pan-macrophages (14.2%) were noticed to
infiltrate the scaffolds implanted in the diabetic environment compared to the nondiabetic (13.5% CD8+ and 1.9% CD68+). (Fig. 4.2 A, B E, F). However, scaffolds seeded
with autologous ASCs lower the level of inflammatory reaction elicited in diabetic rats,
as less accumulation of both T-cells (10.2%) and pan-macrophages (5.0%) was noticed in
cell-seeded versus non-seeded scaffolds implanted in diabetic conditions (Fig. 4.2 C, D,
G, H).

Figure 4.2. IHC and relative DAB:Nuclear Area quantification for CD8 (left panel – A,B,C,D)
and CD68 (right panel – E,F,G,H) as markers for T-cells and pan-macrophages, respectively
(taken at 200X magnification; brown = positive).
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Table 4.1. Relative quantification of IHC images from Fig. 4.2 – (left) CD8 and (right) CD68

4.3.3. ASCs Effect on M1 and M2 Macrophage Polarization
To appraise the number of M1 and M2 macrophages present in implants, sections
were stained for inducible nitric oxide synthase (iNOS), a marker for M1 macrophages,
and CD163, a marker for M2 macrophages. M1 macrophages were seen in abundance in
scaffolds implanted in diabetic rats (20.8%) (Fig. 4.3B) compared to scaffolds implanted
in non-diabetic rats (6.2%) (Fig. 4.3A). In ASC-seeded scaffolds, however, iNOS
expression was significantly lowered (2.1% in control and 3.3% in diabetic) (Fig.
4.3C&D). The opposite trend was seen in expression of CD163: no CD163+ cells (0%)
were detected in acellular elastin scaffolds of glycemic condition (Fig. 4.3E&F).
Conversely, a significant amount of CD163+ cells were observed in elastin scaffolds with
ASCs (20.2% in control and 20.0% in diabetic rats) (Fig. 4.3G&H).

4.3.4. Non-inflammatory Cell Infiltration and ECM Remodeling
In order to evaluate the type of cells involved in tissue remodeling, explanted
samples were assessed by IHC for the presence of smooth muscle and fibroblast-like
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Figure 4.3.

IHC and relative DAB:Nuclear Area quantification for inducible nitric oxide

synthase (iNOS) (left panel – A,B,C,D) and CD163 (right panel – E,F,G,H) as markers for M1
phenotype macrophage and M2 phenotype macrophage polarization, respectively (taken at 200X
magnification; brown = positive).

Table 4.2. Relative quantification of IHC images from Fig. 4.3 – (left) iNOS and (right) CD163
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cells. Cells positive for α-smooth muscle actin (Fig. 4.4B) and vimentin (Fig. 4.4C) as
well as CD34+ cells (Fig. 4.4A) were detected in the adventitia of vascular scaffold.
These cell types did not appear to have a preference for a particular condition, either
control or diabetic. ASC-recellularized scaffolds, however, exhibited greater expression
of CD34 (28% increase in control and 41.6% increase in diabetic) and α-smooth muscle
actin (14.1% increase in control and 12.7% increase in diabetic). Vimentin expression in
either scaffold group remained relatively unchained regardless of glycemic condition of
the rat. Laminin production was also observed throughout the ASC-recelluarized elastin
scaffold, implying that the injected and/or infiltrated cells are attached to the scaffold.
Scaffolds without ASC-recellularization exhibited no endogenous laminin production
(Fig. 4.4).

4.3.5. Calcification and Osteogenic Responses
Alizarin red staining indicates presence of calcium in elastin scaffolds without
ASCs, regardless of glycemic conditions (Fig. 4.5A&D). IHC reveals presence of both
OPN and ALP in control elastin scaffolds without ASCs (Fig. 4.5B&C). OPN and ALP
levels were even more abundant in diabetic elastin scaffolds (Fig. 4.5E&F). No visible
calcium was observed in the control ASC-recellularized elastin scaffolds (Fig. 4.5G).
Similarly, little traces of OPN and ALP (Fig. 4.5H&I) were detected in these scaffolds.
Contrastingly, a significant amount of calcium was observed in the diabetic ASCrecellularized elastin scaffolds (Fig. 4.5J) with high levels of both OPN and ALP (Fig.
4.5K&L). Alizarin red stain indicates no visible traces of calcium regardless of glycemic
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condition or recellularization status after treatment with PGG, a known anti-inflammatory
and anti-oxidative agent (Fig. 4.6A).

Fig. 4.4. IHC for CD34 (A), α-smooth muscle actin (B), vimentin (C), and laminin (D) in elastin
scaffolds with and without ASC-recellularization implanted control and diabetic rats.

Table 4.3. Relative quantification of IHC images from Fig. 4.4.
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Figure 4.5. (Top panel) Implanted elastin scaffolds without ASCs in control (first row) and
diabetic (second row) rats. (Bottom panel) ASC-recellularized elastin scaffolds implanted in
control and diabetic rats. (First column – A,D,G,J) Alizarin Red histological stain for calcium.
(Second column – B,E,H,K) IHC stain for osteopontin (brown = positive). (Third column –
C,F,I,L) IHC stain for alkaline phosphatase (brown = positive).
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Table 4.4. Relative quantification of IHC images from Fig. 4.5 – (left) OPN and (right) ALP

4.3.6. Receptor for Advanced Glycation End Products
Receptors for advanced glycation end products (RAGE), a member of the
immunoglobulin superfamily of cell surface receptors, play an essential role in the
biology of diabetic pathology. We observed higher traces of RAGE in non-treated elastin
scaffolds with ASCs in diabetic conditions (11.3%) compared to control conditions
(2.6%).

These amounts were decreased to 0.9% and 0.6% in control and diabetic

conditions, respectively, in PGG-treated elastin scaffolds with ASCs (Fig. 4.6B).

4.3.7. Cytokines and Mechanical Properties
PGG pre-treatment of scaffolds also significantly inhibit both TGF-β and TNF-α
(Fig. 4.7A&B). The effect of glycemic environment and ASCs on TGF-β and TNF-α
levels are unclear in comparison to the overshadowing effects of PGG on these cytokines.
Diabetes also induced stiffening of ASC-recellularized elastin scaffolds (Fig.4.7C).
ASCs did not appear to have an effect on the mechanical properties of the scaffold. Pretreatment of scaffolds with PGG prior to recellularization and implantation, however, was
able to prevent diabetes-related stiffening without inducing any significant changes to
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native mechanical properties.

These results are consistent with the non-revitalized

scaffolds in Chapter 3.

Figure 4.6. (A) Alizarin Red histological stain of PGG-treated elastin scaffolds with and without
ASC-recullularization in control and diabetic rats. (red = positive). (B) IHC for receptors for
advanced glycation end products (RAGE) of non-treated and PGG-treated elastin scaffolds
recellularized with ASCs in control and diabetic rats (brown = positive).

Table 4.5. Relative quantification of IHC for RAGE from Fig. 4.6
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Figure 4.7. (A) ELISAs for TNF-α and (B) TGF-β content in extracted protein, normalized to
total protein. (C) Biaxial tensile tests showing tension (N/m) vs. stretch in both circumferential
and longitudinal directions of ASC-recellularized elastin scaffolds.

4.4. Discussion
Recellularization of acellular matrix scaffolds with an appropriate cell source is
actively being researched as a key component in many cardiovascular tissue engineering
paradigms36,

37

.

The use of adipose stem cells was chosen due to its high clinical

potential23, 25. Our ASC-recellularization did not achieve vascular cell density equal to
native conditions; however, complete recellularization was not the goal of this study.
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Rather, the objective was to seed all of the isolated ASCs into the scaffold to examine the
effect of these stem cells on elastin scaffolds in diabetes.
We have previously highlighted the increased inflammation caused by diabetes on
acellular elastin scaffolds20. The source of increased inflammation stems from a variety
of factors including elevated oxidative stress and decreased activity of endogenous
antioxidants in diabetes7,

9, 38

.

Specifically, glucose can undergo autoxidation and

generate OH- radicals. In addition, glucose can react with proteins to form advanced
glycation end products (AGEs).
formation.

ROS is generated at multiple steps during AGE

In hyperglycemic conditions, there is enhanced metabolism of glucose

through the polyol pathway, which also results in enhanced production of reactive
oxygen4, 7, 39. It is believed that the increased oxidative stress in diabetes is the primary
source of chronic inflammation and cardiovascular disease12.

Previously, we have

shown anti-inflammatory effects of PGG as a matrix-binding stabilizing agent in
diabetes20. Because ASCs play a pivotal role in our tissue engineering paradigm, or goal
was to investigate the potential immunomodulatory properties ASCs possess to aid in
rendering cardiovascular tissue engineered constructs diabetes-resistant. ASCs have been
documented to downregulate Th1 cytokines and improve overall Th1/Th2 balance40 by
stimulating production of anti-inflammatory cytokines such as IL-4 and IL-1028.
Moreover, both ASCs and other mesenchymal stem cells have been shown to suppress Tcell proliferation and cytokine production40. Though initial studies have suggested that
ASCs can trans-differentiate along a particular lineage pathway to replace target cell
populations, many tracking studies in animal models do not consistently support this
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paradigm anymore24. It has now been suggested that ASCs act through paracrine release
of growth factors required to accelerate and direct tissue repair by endogenous or hostderived cells41-43. Furthermore, ASC have been shown to secrete immunomodulatory
factors such as prostaglandin to suppress inflammatory responses following ischemic
events, thus enhancing recovery44.

We noticed an excessive inflammatory response to

the acellular elastin scaffolds implanted in diabetic rats (Table 4.1): 29.3% T-cells and
14.2% macrophages of total cells infiltrated; none of these cells were M2 macrophages
(Fig. 4.3). These inflammatory cells are an increase from the 13.5% T-cells and 1.9%
macrophages of total cells infiltrated from non-diabetic rats; again, none of these cells
were M2 macrophages. Consequently, we presumed that tissue engineered ECM-based
vascular scaffolds implanted in diabetic conditions might undergo impaired remodeling
and healing, due to chronic inflammation. It has been demonstrated that the host innate
immune system responds to implanted biomaterials by recruiting macrophages that
amplify the inflammatory response and subsequently send signals to T-cells. However,
the ECM-based scaffolds have been shown to promote a switch in the macrophage
population from a predominantly pro-inflammatory M1 phenotype to predominantly
reparative M2 macrophages, which secrete anti-inflammatory mediators45, 46. We noticed
these facts in scaffolds implanted in control rats, but not in diabetic rats. These
observation are in agreement with studies that show that in diabetes, the combination of
persistent hyperglycemia and oxidative stress associated with decreased activity of
endogenous antioxidants, lead to chronic inflammation, delayed or impaired wound
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healing and reduced ability to transition from a M1 to a M2 phenotype macrophages
38

7, 9,

.
As expected, higher levels of M1 phenotype macrophages are seen in scaffolds

implanted in diabetic rats (Fig. 4.3B) compared to that of control rats (Fig. 4.3A).
Moreover, the ratio of M1 to M2 macrophages is heavily skewed in diabetic
environments towards M1 polarization with little to no expression of CD163+ M2
macrophages (Fig. 4.3F). The pro-inflammatory diabetic environment is conducive to
M1 phenotype polarization of macrophages.

M1 macrophages are responsible for

chronic inflammation, promoting muscle damage, and generating copious amounts of
toxic reactive oxygen intermediates and cytokines such as IL-6, TNF-α, and nitric oxide
which is generated by an overabundance of iNOS

33, 34

. However, we demonstrate the

immunomodulatory properties of the seeded ASCs onto the elastin scaffold prior to
implantation are inhibiting the M1 macrophage polarization that was so prevalent in
diabetic conditions (Fig. 4.3D). Even more interesting, we see much greater polarization
of macrophages towards the M2 phenotype in both control (Fig. 4.3G) and diabetic
conditions (Fig. 4.3H). The ability of ASCs to shift the Th1/Th2 balance in favor of
constructive tissue remodeling in not only control environments but also diabetic
environments is extremely promising for future applications of tissue engineering
therapies for a wide variety of patient populations.
The presence of CD34+ cells (Fig. 4.4) is indicative of potential constructive
tissue remodeling and cell recruitment.

In addition, these CD34+ cells also indicate

possible continued immunomodulation at the implant site after implantation. It is also
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important to note the ability of ASC-recellularized elastin constructs to encourage
relevant vascular cell infiltration such as smooth muscle cells and fibroblasts. ASCs do
not prevent or hinder infiltration of target cell types such as smooth muscle cells (SMCs)
(Fig. 4.4). We have also previously reported the loss of laminin after decellularization of
the porcine carotid artery to produce the elastin scaffold20. The loss of this basal lamina
protein presented a potential drawback to the future use of our scaffold due to its vital
role in cell adhesion and signaling pathways19,

47, 48

.

Laminin is an integral ECM

component and has been shown to be involved in adhesion-mediated events such as cell
proliferation, differentiation, and maturation49,

50

.

We see, however, endogenous

production of laminin after implantation (Fig. 4.4) suggesting a positive outlook on the
use of our elastin scaffold for vascular applications.
Elastin calcification is another threat to the downstream application of our elastin
scaffold. Elastin scaffolds have been shown to readily calcify in vivo

20, 51, 52

. What’s

more alarming is that vascular calcification and atherosclerosis is already prevalent,
especially in patients with diabetes53, 54. It makes little sense to replace a calcified artery
with a calcification-prone elastin graft. The mechanism of diabetic calcification in vivo is
still not fully understood, however it is believed to be caused by chronic inflammation
and oxidative stress similar to that seen in atherosclerosis and end stage renal disease
(ESRD)

55-58

. Furthermore, osteogenic transformation of medial graft SMCs was shown

to occur alongside up-regulated pro-inflammatory response caused by TNF-α

59

and

TGF-β60, 61. Also, osteogenic differentiation of mesenchymal stem cells was shown to be
possible in inflammatory environments62. Specifically, osteopontin is reported to be
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upregulated at inflammatory sites, particularly biomaterial implant sites63. Aspects of
diabetes such as hyperglycemia, excessive insulin, and hypoxia can all lead to increased
osteopontin expression in SMCs54,

64, 65

.

We have previously reported in vivo

calcification of elastin scaffolds regardless of glycemic environment20 with calcium
staining (Fig. 4.5 A,D). The presence of osteogenic markers osteopontin (Fig. 4.5B,E)
and alkaline phosphatase (Fig. 4.5C,F) are prevalent in both control and diabetic rats.
From these results, it is still unclear whether or not there are higher levels of calcification
in the diabetic conditions compared to control. Astonishingly, we see no visible traces of
calcium in ASC-recellularized elastin scaffolds implanted in control rats along with
significantly reduced levels of osteopontin and alkaline phosphatase.

ASC-

recellularization seems to have little effect on calcium deposition (Fig. 4.5J) and
osteogenic expression (Fig. 4.5K,L) in diabetic rats.

It is possible that the

immunomodulation provided by the ASCs are actively inhibiting calcification in the
mild-inflammatory environment in control conditions. However, the propensity of ASC
immunomodulation is overwhelmed in the aggressive inflammatory environment
afforded by diabetic conditions thus allowing inflammation-driven calcification to occur.
PGG has been demonstrated to have a multitude of beneficial pharmacologic and
biologic properties including anti-inflammatory, anti-oxidant, and anti-cancer

66

. Our

goal was to utilize, in particular, anti-oxidant and anti-inflammatory properties of PGG to
reduce diabetic complications of tissue engineered constructs.

Remarkably, all

histologically detectable calcification was inhibited after PGG-treatment of either nonseeded or ASC-seeded elastin scaffolds in both control and diabetic conditions (Fig.
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4.6A).

In diabetes, besides the excessive inflammatory, there is also an increased

oxidative environment, well illustrated by the activation of RAGE, which stimulates an
overproduction of ROS67. The amount of RAGE was also reduced in the presence of
PGG. (Fig. 4.6B). Many publications have showed that stimulation of RAGE results in
NADPH oxidase and mitochondrial dependent ROS generation68,

69

; superoxide

generation by dysfunctional mitochondria in diabetes has been postulated as the initiating
event in the development of diabetic complications38. It is possible that, while ASCs
reduce inflammation, the anti oxidative treatment of scaffolds with PGG prevents the
expression of RAGE on injected and/or infiltrated cells, inhibiting the process of
calcification.
A drastic decrease in both TNF-α (Fig. 4.7A) and TGF-β (Fig. 4.7B) was seen in
PGG-treated scaffolds.

No outstanding difference in these cytokines was observed

between non-seeded and ASC-recellularized elastin scaffolds. While it is possible that
the ASCs are actively participating in cytokine release and modulation, their activity is
dwarfed by the effect of PGG. PGG has a markedly noticeable effect on both TGF-β and
TNF-α, suggesting its ability to overpower the aggressive inflammation in diabetes.
ASC-recellularization does not seem protect the scaffold from diabetes-related stiffening
(Fig. 4.7C); however, the protection from stiffening is still offered by PGG-treatment.
The ASCs do not contribute significantly to mechanical properties of implanted elastin
scaffolds (Fig. 4.7C) compared to previously reported non-seeded counterparts20
suggesting that ASCs do not significantly prevent scaffold cross-linking in diabetes. The
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preservation of mechanical properties akin to that of PGG-treated scaffolds implanted in
control rats is seen in PGG-treated scaffolds implanted in diabetic rats.
While the immunomodulation of ASCs ameliorate some aspects of inflammation
and calcification, PGG stabilization of biologic scaffolds remains a good option to
achieve a truly diabetic resistant tissue engineered construct. Tissue engineering for the
treatment of cardiovascular disease holds a promising future; however, its fate rests on its
ability to not only address the disease but also the comorbidities of the patient. Diabetes,
a major risk factor for cardiovascular disease, must be addressed as therapies in tissue
engineering approach clinical feasibility. Rampant inflammation in diabetes will lead to
chronic wound healing of the implant site, scaffold calcification, and ultimately graft
failure. We have demonstrated that recellularization of scaffolds with autologous stem
cells, a key component of the tissue engineering paradigm, may intrinsically aid in
fighting diabetes-related complications seen in implanted grafts.

4.5. Conclusion
The immunomodulatory capabilities of adipose stem cells may, indeed, contribute
to overall favorable outcomes post-implantation into a diabetic environment by shifting
to a constructive Th2 response. Nonetheless, the chronic oxidative, inflammatory milieu
that diabetes elicits can still overwhelm ASC’s immunomodulatory properties therefore
necessitating the need PGG, an antioxidant polyphenol capable of binding to extracellular
matrix scaffolds. PGG not only provides an extra means for anti-inflammation, but also
is essential in preventing elastin scaffold calcification, particularly in diabetes.
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A

foreseeable end goal is the synergistic harmony between PGG-treatment and ASCrecellularization of elastin scaffolds for a practical means to achieve clinical translation of
vascular tissue engineering in patients with diabetes.
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CHAPTER 5: CHARACTERIZATION OF ADIPOSE STEM CELL
DIFFERENTIATION IN THE 2D AND 3D DIABETIC ENVIRONMENT
	
  
5.1. Introduction
In order for tissue-engineered constructs to survive long-term implantation, they
must be capable of not only host integration, but also gradual remodeling and
maintenance. The human body is considered a harsh environment not only because of
complex homeostatic mechanisms, but also constant mechanical stress and acute injury.
For example, the aortic heart valve is considered the most mechanically stressed tissue in
the human body1. In normal activity, the valve experiences pressure change from 10 to
120 mmHg in less than 0.1 seconds. Furthermore, in the valve undergoes this cycle of
extreme pressure and shear stress for an average of 8 billion times in a lifetime. There is
currently no synthetic construct – either valvular or vascular – on the market that can
withstand the demanding environment afforded by the human body.
There also exists the problem of pediatric patients. Cardiovascular prostheses on
the market have no remodeling capability that will grow with these patients. As a result,
multiple follow-up surgeries for size-appropriate device replacements are required for
pediatric patients, which can be both painful and traumatic.
Tissue engineered structures require a resident cell population that is capable of
remodeling and maintaining the local site during growth and wound healing. In a
common paradigm of patient-tailored tissue engineering (Fig. 5.1), we combine
autologous adult adipose stem cells with a biologic scaffold together to form a tissue
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engineered construct. The characterization of scaffolds and the effect of stem cells have
been reviewed in the previous chapters (chapters 3 and 4).

Fig. 5.1. Our overall approach to the tissue engineering paradigm – starts with the patients and
ends with the patient.

Functional (circulatory) implantation of tissue engineered constructs, however, are not
expected to integrate in the human body without mechanical preconditioning.
Preconditioning in a bioreactor subjects the construct to relevant physiologic stresses and
strains akin to that experienced in the native environment. The role of mechanical inputs
has shown to be vital in determining cell metabolism and phenotype due to
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mechanotransduction and tensegrity-based mechanosensing2, 3. In vitro maturation of
constructs in a bioreactor also plays an essential role in cell proliferation, cell activation,
establishing early ECM elaboration4. In addition to providing mechanical stresses, the
bioreactor also allows for three-dimensional biochemical mass transport of oxygen and
growth factors to further mimic the native physiological environment. The combinations
of various stimuli in the bioreactor are expected to provide the relevant signals necessary
for ASC differentiation into target cardiovascular cell (e.g. VICs for valves, SMCs and
ECs for vessels). ASCs have demonstrated the potential for differentiation into vascular
and valvular cells especially once isolated from the stromal vascular fraction5, 6. The
phenotypic characteristics of ASCs are similar to that of bone marrow stromal cells6.
As briefly mentioned in Chapter 4, ASCs show excellent potential for use in
vascular tissue engineering. Importantly, ASCs have the ability to differentiate into
endothelial cells, creating a non-thrombogenic blood-tissue interface that regulates
inflammatory and immune reactions7; into smooth muscle cells, responsible for
vasoconstriction and dilation in response to normal and pharmacologic stimuli; and into
fibroblasts, involved in synthesis of collagen, elastin, and proteoglycans and secretion of
growth factors and cytokines. Adipose stem cell immunomodulation holds high potential
for tissue engineered construct integration. ASCs are able to suppress T-cell proliferation,
reduce inflammatory cytokines, and stimulate production of anti-inflammatory cytokines
such as IL-4 and IL-10. The immunomodulatory impact of ASC has already been
demonstrated in a variety of experimental models of disease, including spinal cord injury,
neurodegenerative diseases, and GvHD. Results from clinical trials have confirmed the
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safety and efficacy of ASC in treating a variety of diseases, including diabetes mellitus.
Diabetic patients infused with bone marrow and ASCs had a 40% decrease in insulin
requirements with no adverse effects in a 3 months follow-up period. Studies evaluating
the therapeutic impact of ASC in patients with DM foot showed improved rest pain score,
walking time, and evidence of increased vascular collateral networks within 6 months of
intramuscular ASC injection. Besides immunosuppressive molecules, ASCs also secrete
soluble factors that promote tissue regeneration at the injury site via a paracrine
mechanism: angiogenic factors (VEGF), anti-apoptotic factors (IGF-1), hematopoietic
factors (colony stimulating factors and interleukins), transforming growth factor-β1 and
hepatic growth factor. Furthermore, adipose stem cells have been shown to regulate
macrophage activation by suppression of classically activated M1 macrophages in favor
of alternatively activated M2 macrophages, providing a therapeutic effect in wound
healing.8 In order to precondition the cell seeded scaffolds and induce tissue maturation,
mechanical and biochemical stimuli are required before implantation 9, 10 in animals 11-13.
We hypothesize that the efficacy of differentiation of adipose stem cells into
target vascular cells will be altered by diabetes in a controlled biochemical and
biomechanical environment.

5.2. Materials and Methods
5.2.1. 2D Endothelial and Smooth Muscle Cell Culture
Human aortic endothelial cells (hAECs) (#PCS-100-011, ATCC, passage 1) were
obtained and expanded in Endothelial Cell Growth Kit (VEGF enriched) (#PCS-100-041,
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ATCC) with 1% antibiotic solution (Corning – Cellgro). HAECs were maintained and
subcultured at subconfluent conditions on tissue culture plastic with Trypsin-EDTA for
Primary Cells (#PCS-999-003, ATCC) and Trypsin Neutralizing Solution (#PCS-999004, ATCC).

To obtain high glucose media, D-(+)-Glucose Monohydrate

(#EM1.08342.1000, VWR) was added to the Endothelial Cell Growth Kit to a
concentration of 5.5g/L. HAECs were cultured for up to 6 weeks in both control and
high glucose concentrations.
Human smooth muscle cells (hSMCs) (#C-007-5C, Life Technologies) were
obtained and expanded in media comprised of Dulbecco’s Modification of Eagle Medium
(DMEM, Corning-Cellgro) supplemented with 10% fetal bovine serum (FBS, Atlanta
Biologicals, Atlanta, Georgia) and 1% antibiotic solution. HSMCs were maintained and
subcultured on tissue culture plastic with Trypsin-EDTA 1X (#25-053-CI, CorningCellgro).

To

obtain

high

glucose

media,

D-(+)-Glucose

Monohydrate

(#EM1.08342.1000, VWR) was added to the media to a concentration of 5.5g/L. HSMCs
were cultured for up to 6 weeks in both control and hyperglycemic conditions.
5.2.2. 2D ASC Culture
Human adipose tissue was collected according to the procedures within an
approved IRB protocol (Institutional Review Board) with the Greenville Health System
(GHS). The fat was minced into fine pieces using scalpel blades and placed into a
solution of collagenase type I (1 mg/mL, #NC96336323, Fisher Scientific) in 1x PBS and
incubated at 37°C for 1 hour under agitation. Following digestion, the solution was
filtered through 100 µm sieves and centrifuged at 1000 rpm for 5 minutes. Once the
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supernatant was decanted, the cell pellet was resuspended in a solution of 155 mM
ammonium chloride (NH4Cl, #BDH0208, Fisher Scientific) and 0.1 mM EDTA (#E6511,
Fisher Scientific) in 1x PBS for 5 minutes at room temperature to lyse any residual
erythrocytes. The solution was then centrifuged at 1000 rpm for 10 minutes, the
supernatant decanted, and the pellet resuspended in MesenPRO RS Medium (#12746012, Life Technologies), the cells counted, and plated in tissue culture-treated flasks at a
density of 5000 cells/cm2. Adherent adipose stem cells (ASCs) were maintained at subconfluent levels and replated at 5000 cells/cm2 twice to yield 4 separate flasks of ASCs.
Each flask was then designated to (1) control SMC differentiation, (2) control EC
differentiation, (3) diabetic SMC differentiation, or (4) diabetic EC differentiation.

5.2.3. 2D EC and SMC Differentiation
For differentiation of ASCs to endothelial-like cells, ASCs were cultured for up to
4 weeks in EC differentiation media comprised of DMEM, 2% FBS, and 1% antibiotic
solution supplemented with 0.5 ng/mL vascular endothelial growth factor (VEGF, #10020B, PreproTech Inc) and 20 ng/mL insulin-like growth factor-1 (IGF-1, #AF-100-11,
PeproTech Inc). Growth factors were freshly added to the media at the time of each
media change.

Diabetic EC differentiation media was generated by adding D-(+)-

Glucose Monohydrate to a concentration of 5.5 g/L. ASCs were cultured in either control
or diabetic EC differentiation media for up to 4 weeks on tissue culture plastic.
For differentiation of ASCs to smooth muscle-like cells, ASCs were cultured for
up in SMC differentiation media comprised of DMEM, 1% FBS, and 1% antibiotic
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solution supplemented with 5 ng/mL transforming growth factor beta (TGF-β1, #10021C, PeproTech Inc) and 2.5 ng/mL bone morphogenic protein 4 (BMP-4, #120-05,
PeproTech Inc). Growth factors were freshly added to the media at the time of each
media change. Diabetic SMC differentiation media was generated by adding D-(+)Glucose Monohydrate to a concentration of 5.5 g/L. ASCs were cultured in either control
or diabetic SMC differentiation media for up to 4 weeks on tissue culture plastic.

5.2.4. Investigation of Cell Phenotype (Immunofluorescence Visualization)
Immunofluorescence (IF) was performed on the ASCs undergoing EC and SMC
differentiation at three separate time points: time zero, 2 weeks, and 4 weeks. Prior to
IF, cells were passaged, plated on 6-well plates, and cultured until the end of each time
point. To perform IF, media was removed and wells were washed with 1X PBS one
time.

After removal of PBS, cells were covered with 4% paraformaldehyde and

incubated for 15 min at room temperature. After the fixative was removed, cells were
rinsed 5 times with 1X PBS for 5 min each. Cells were then blocked in blocking buffer
(1X PBS, 5% Normal Horse Serum, 0.3% Triton X-100) for 60 min at room temperature.
After removal of blocking buffer, diluted primary antibody was added. The antibody
diluent buffer (1X PBS, 1% bovine serum albumin, 0.3% Triton X-100) was used to
dilute stock antibodies:

rabbit anti-CCR7 (CCR7, 1:250 dilution, #CG1678, Cell

Applications), Mouse/Rat Polyclonal to CD34 (CD34, 3µg/mL working concentration,
#AF6518, R&D Systems), rabbit polyclonal to α-smooth muscle actin (α-SMA, 1:100
dilution, #ab5694, Abcam), mouse monoclonal to smooth muscle myosin heavy chain
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(SMM-hc, 1:250 dilution, #ab683, Abcam), rabbit polyclonal to CD31 (CD31, 1:20
dilution, #ab28364, Abcam), and rabbit polyclonal to vascular endothelial cadherin (VECadherin, 5µg/mL working concentration, #ab33168, Abcam). Cells were incubated in
diluted primary antibody overnight at 4°C under slight agitation. After rinsing 3 times in
1X PBS, cells were incubated in fluorochrome-conjugated secondary antibody diluted in
antibody diluent buffer for 1 hour at room temperature in the dark.

Fluorescent

secondary antibodies – Goat anti-rabbit IgG DyLight 488 (#ab96899, Abcam), donkey
anti-sheep IgG AlexaFluor 647 (#A21448, Life Technologies), and donkey anti-mouse
IgG AlexaFluor 488 (#A21202, Life Technologies) – were diluted to 4µg/mL prior to
incubation. Cells were then rinsed in 1X PBS once and incubated in DAPI solution at a
concentration of 1µg/mL (#D9542, Sigma) for 15 minutes. Cells were rinsed one last
time in 1X PBS and imaged via fluorescence microscopy immediately.

5.2.5. Vascular Elastin Graft Preparation and Seeding
Decellularized elastin scaffolds (see Chapters 3 & 4) were seeded with expanded
hASCs not subjected to growth factors to yield a vascular graft. Ten vascular grafts (~67cm in length) were seeded to both the adventitia and the lumen. A total of 2.5X106
ASCs were carefully seeded into the media at multiple sites along the scaffold media with
a 30G syringe needle. Another 2.5X106 ASCs were injected into the lumen of the graft;
subsequently, the grafts were sealed shut by capped barbed luers. Vascular grafts were
maintained in a cell culture incubator in DMEM, 10% FBS, and 1% antibiotic solution
and turned 90° every 4 hours to ensure adequate luminal coverage by the ASCs.
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5.2.6. Vascular Bioreactor Design
To mimic physiological conditions in vitro, we developed a vascular bioreactor
based on a similar design by Lee Sierad. The vascular bioreactor was constructed in
SolidWorks and machined by the Clemson Machining and Technical Services. Designed
to accommodate 5 vascular grafts up to 4 inches long, the vascular bioreactor features
some improvements over its predecessor including stainless steel “quick” barbed fittings
(fittings with O-ring seal rather than threading seal), larger size, aluminum base, acrylic
chamber, polycarbonate lid, and air bubble catchers.

Overall, this bioreactor was

designed to be constructed quickly with less risk of contamination.

5.2.7. Bioreactor Conditioning
Vascular grafts were mounted into the bioreactor (5 per bioreactor) by attaching
each graft end to the stainless barbed fittings. Grafts were fastened to each barb using
flush-fit zip ties. Two bioreactors were used to mechanically condition the vascular
grafts – one diabetic and one control. The diabetic media was comprised of DMEM,
10% FBS, and 1% antibiotic solution and supplemented with glucose to a concentration
of 5.5 g/L. Control media was made the same way sans additional glucose. A peristaltic
pump (Cole Parmer) was used to perfuse media at a rate of 1 mL/min through the lumen
and throughout the chamber to fully bathe the grafts in media. The vascular grafts were
dynamically cultured for up to 2 weeks in a cell culture incubator with static grafts
serving as a control.
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5.2.8. Histological Analysis of Vascular Constructs
Cell viability and cytotoxicity of the vascular grafts were evaluated using
Live/Dead Viability Assay Kit (Life Technologies). A small section was cut from the
center of the graft and stained with contents of the kit according to the procedure
provided by the manufacturer. The luminal side of the section (the area exposed to
dynamic flow) was imaged via fluorescence microscopy.
Both dynamically and statically conditioned vascular grafts were placed in 10%
nueutral buffered formalin (Fisher Scientific) for over 24 hours and processed through a
tissue processor for histological evaluation. Immunohistochemistry (IHC) was performed
on rehydrated paraffin sections (5µm) to examine presence of α-SMA, SMM-hc, CD31,
VE-cadherin, CCR7, and CD34.

Briefly, heat-mediated antigen retrieval was

implemented by immersing sections in 95-100°C solution of 10mM citrate buffer (pH
6.0) for 20 min. Sections were then treated with 0.025% Triton X-100 for 10 min and
blocked in 1.5% normal horse serum for 30min. Endogenous peroxidases were blocked
with 0.3% hydrogen peroxide in 0.3% horse normal serum for 30 min then primary
antibody was applied for 1 hour at room temperature, followed by incubation in
appropriate biotinylated secondary antibody (1:200 dilution, Vector Labs) for 30 min.
VECTASTAIN Elite ABC Reagent, R.T.U. was applied, and the chromogen was
visualized using the DAB Peroxidase Substrate Kit. Negative staining controls were
obtained by the omission of the primary antibody. Sections were lightly counterstained
with hematoxylin, prior to mounting. Digital images were obtained at various
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magnifications (100X to 200X) on a Zeiss Axiovert 40CFL microscope using AxioVision
Release 4.6.3 digital imaging software (Carl Zeiss MicroImaging, Inc. Thornwood, NY).

5.3. Results
5.3.1. Effect of High Glucose Concentrations on ECs and SMCs in 2D
High glucose media did not appear to have much effect on hECs after 6 weeks.
Expression of CD31 and VE-Cadherin remained fairly consistent after 4 weeks of culture
in the diabetic culture environment (Fig. 5.2). Expression of both α-SMA and SMM-hc
was also seen after 6 weeks in high glucose conditions with no apparent difference from
the 6-week control in terms of fluorescence (Fig. 5.2). However, a slightly higher rate of
proliferation of the SMCs was observed in the diabetic conditions with a cell count
approximately 13% higher after each passage. This higher proliferation rate was not
exhibited by the diabetic hECs.
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Fig 5.2. Immunofluorescence for human endothelial cells (stained with CD31 and vascular
endothelial cadherin) and human aortic smooth muscle cells (stained with alpha-smooth muscle
actin and smooth muscle myosin heavy chain) cultured at time zero and after 6 weeks of control
and diabetic media.

5.3.2. Effect of High Glucose Concentration on ASC Differentiation in 2D
At time zero, it was established that low passage hASCs strongly express of
CCR7, a known mesenchymal stem cell marker; however, expression of CD34 was not
observed. No expression of SMC markers (α-SMA and SMM-hc) or EC markers (CD31
and VE-cadherin) was seen in these hASCs at time zero (Fig. 5.3A).
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After 4 weeks of culture without growth factors, CCR7 expression still remained
prevalent in the hASCs in both control and diabetic conditions. Slight expression of αSMA was also observed after 4-week culture in both conditions. However, no smooth
muscle myosin or endothelial cell markers were observed in either condition (Fig. 5.3B).
After 4 weeks of culture with growth factors specific to either endothelial cells or
smooth muscle cells, some phenotypic modulations were seen via immunofluorescence.
For hASCs cultured in EC differentiation media for 4 weeks, no CD31 was observed in
either control or diabetic conditions.

Conversely, VE-cadherin was seen in both

conditions (Fig. 5.3B). No expression of α-SMA and SMM-hc was seen in the ASCs
cultured in SMC differentiation media for 4 weeks, suggesting that high glucose impairs
this particular differentiation (Fig. 5.3B).

5.3.3. Efficacy of New Vascular Bioreactor
During dynamic culturing of the vascular grafts with the vascular bioreactor, no
observable leaks were detected, indicating adequate size matching of the O-rings on both
the chamber lid and the quick fittings. Full set up time for this bioreactor was 30
minutes, whereas with the old vascular bioreactor, at least 1 hour was necessary for full
installation (Fig. 5.4).
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Fig. 5.3A. Immunofluorescence stain for CCR7, CD34, alpha smooth muscle actin,
smooth muscle myosin heavy chain, CD31, and vascular endothelial cadherin in low
passage hASCs (time zero) cultured in 2D. Blue = Nuclei. Green = Positive Stain.
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Fig. 5.3B. Immunofluorescence of hASCs subjected to 4 weeks in growth factor-enriched media
(right side) – endothelial differentiation media (stained with CD31 and vascular endothelial
cadherin) and smooth muscle cell differentiation media (stained with alpha-smooth muscle actin
and smooth muscle myosin heavy chain) in control and diabetic conditions. HASCs cultured for
4 weeks without differentiation media shown as a control (left side). Blue = Nuclei. Green/Red
= Positive stain.
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Fig. 5.4. SolidWorks drawing (top left) and macro images of bioreactor chamber, base, and lid
with “quick-connect” barbed luers.
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Live cells were seen exclusively in the bioreactor conditioned vascular grafts in
both control and diabetic conditions, whereas only dead cells were observed in the static
controls. While alignment of live cells in the direction of media flow was witnessed in
both conditions, the alignment was much more significant in control conditions (Fig.
5.5A).

Fig. 5.5A. Live/Dead stain of calcein AM (green) to indicate live cells and ethidium homodimer
(red) to indicate dead cells in control and diabetic conditions of dynamically and statically
cultured vascular grafts. Green = Live. Red = Dead.
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5.3.4. Morphology and Phenotype Evaluation of Conditioned Vascular Constructs in 3D
At time zero (after 16 hours post-seeding incubation), boluses of hASCs could be
seen in the cross section of the grafts. A monolayer of hASCs lining the internal elastic
lamina in the lumen could also be detected. After the 2-week dynamic culture, the
boluses of cells were less apparent as the cells seemed to migrate from the bolus site to
adjacent areas in the media. Fewer cells were detected in the lumen after 2 weeks than at
time zero (Fig. 5.5B).
α-SMA was detected at all phases of seeding – from time zero to 2 weeks, with
no observable difference between control and diabetic conditions. More α-SMA was
detected at time zero due to presence of the cell bolus; as the cells migrated, the density
of α-SMA+ cells became sparser. Unlike smooth muscle actin, expression of SMM-hc
was not readily seen; the elastin fibers exhibited traces of pseudo-positive staining, even
in areas where no cells were present. Little to no expression of VE-cadherin was seen at
time zero, but did being to appear after 2-week dynamic culture. Upon 2 weeks, VEcadherin was seen both along the lumen as well as in the cell boluses. Expression of
CD31 by the cells remained largely absent throughout all phases of the culture in both the
media and the lumen (Fig. 5.5B).
The effects of high glucose conditions in this experiment remain unclear; the
diabetic environment did not induce any noticeable modulation of hASC phenotype
towards SMCs or ECs. It is clear, however, that the mechanical stresses afforded by the
vascular bioreactor induces significant changes to the vascular construct in terms of cell
retention and migration.
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Fig. 5.5B. IHC of vascular constructs at (left column) time zero, (middle column) 2-week post
control bioreactor, and (right column) 2-week post diabetic bioreactor stained for CCR7, CD31,
VE-Cadherin, α-SMA, and SMM-hc. Brown = Positive. Purple = Nuclei.
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5.4. Discussions
As it stands with the study, the term “diabetic” environment is used quite loosely.
When we refer to this term, we are focusing directly on the high glucose aspect that’s
prevalent in patients with diabetes. The non-enzymatic crosslinking reaction of glucose
with proteins, lipids, and nucleic acids is thought to be one of the root causes for the
development of cellular dysfunction which leads to cardiovascular disease14. We are not
taking into consideration the other metabolic imbalances associated with the diabetic
environment involving insulin, triglycerides, and cholesterol. Indeed, the combination of
metabolic abnormalities along with glycoxidation and reactive oxygen radicals intensely
exacerbates the pathogenesis of diabetes-related disease15-17. For the purposes of this
study, however, we focused on the effects of the high glucose concentration environment
on stem cell differentiation and viability in 3D coupled with relevant mechanical forces
that would be seen in native physiologic conditions. Our objective was to see scrutinize
stem cell differentiation in both 2D vs. 3D to determine optimum vascular graft
development.

We noticed that growth factors were necessary for differentiation of

hASCs into SMCs and ECs. While CD31 was not readily expressed after exposure to EC
differentiation media, VE-cadherin expression was seen. While VE-cadherin is usually
only seen at cell-cell interactions, the upregulation of VE-cadherin has also been shown
to be associated with significant accumulation of β-catenin, which can also yield a VEcadherin positive stain18. This result suggests that the high glucose environment either
inhibits or slows endothelial cell differentiation of ASCs.
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The presence of α-SMA in ASCs without SMC differentiation media is not
alarming; this result has been supported by several other groups who claim that ASCs
express α-SMA upon prolonged culture19, 20. Therefore, the use of α-SMA, alone, as a
marker for the determination of SMC differentiation is insufficient. However, when
coupled with smooth muscle myosin heavy chain, a late marker for smooth muscle
cells21, SMC differentiation looks much more promising particularly since time zero
controls exhibited no SMM-hc expression.
Clearly, the effectiveness of growth factor-enriched media specific for SMC and
EC differentiation of ASCs cannot be ignored. The limitation to this technique, however,
is that it is constrained only to two-dimensional cultures.

In native physiologic

environments, cells interact within a three-dimensional matrix framework, which plays a
large role in cell signaling, communication, remodeling, and phenotypic modulation3, 22,
23

. The role of bioreactor-induced mechanical signals has also been shown to play a vital

role in stem cell differentiation to target vascular cells24-26. In our studies, we did not
observe drastic SMC or EC differentiation of stem cells on vascular constructs due to
mechanical stress alone. Similar to the 2D differentiation cultures, CD31 was not seen
throughout the vascular grafts while VE-cadherin was. Both SMC markers also stained
positive in the dynamically conditioned vascular grafts in both control and diabetic
conditions. The most drastic change to the grafts was elicited by the mechanical flow and
shear stress, thus overshadowing any potential effects of diabetes. While the efficacy of
differentiation of ASCs into relevant vascular cells still remains unclear, we see major
changes to cell morphology, viability, and migration; static counterparts did not survive
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the 2-week culture (Fig. 5A). Cell survival and proliferation are essential to vascular
graft viability post-implantation in a translational scenario.
There is some controversy of the use of CD34 as a marker for ASCs27 because it
has been shown to stain positive for other progenitor cells found in the same population
as adipose derived tissue stromal cells (hematopoietic cells, endothelial progenitor cells,
etc.). ASCs have been shown to be CCR7+, CD34+, CD90+, CD140+, CD133-, and
CD45- 19, 28; isolation of pure ASCs from the stromal vascular fraction would require a
much more thorough screening process and separation via flow cytometry. The lack of
CD34 expression (Fig. 5.3A&B) does not necessarily indicate the lack of ASCs in the
culture; in fact, studies have shown ASCs devoid of CD34 expression in 2D cultures29, 30
and full of CD34 expression in 3D and some 2D cultures31, 32. We have seen firsthand
seen the reason for this controversy with varying expressions of CD34 (See Chapter 4).
The lack of CD31 expression combined with the positive expression of CCR7, however,
is a positive indication that the population of cells are primarily a homogeneous culture of
ASCs with no endothelial progenitor cells33.
While the high glucose diabetic environment did not appear to have an effect on
the phenotype of somatic human SMCs (Fig. 5.2), it did cause a higher rate proliferation,
which was not observed by the endothelial cells.

One of the effects of advanced

glycation end products has relevant to vascular disease is the induction of smooth muscle
cell proliferation14, 34. It is possible that endothelial cells are able to withstand the effects
of AGEs more readily than SMCs; after all, ECs are the first line of defense in the bloodcontacting surface of the endothelium. It is clear, however, that endothelial cells are not
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immune to dysfunction, which is one of the major mechanisms underlying accelerated
atherosclerosis in patients with diabetes35.

5.5. Conclusions
More sensitive biochemical assays will be necessary to elucidate the potential
adverse effects of diabetic conditions on ASC differentiation into target vascular cells.
Perhaps the best method for the creation of a viable vascular construct lies with
combination of relevant growth factors necessary for differentiation and mechanical
conditioning and mass transport of nutrients offered by the vascular bioreactor for
construct viability and graft survival.

A synergistic effect by growth factors and

bioreactor holds high potential to yield the next generation of personalized medicine by
paving the way for a robust and much-needed tissue engineered vascular replacement.
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CHAPTER 6: CONCLUSIONS AND RECOMMENDATIONS FOR FUTURE
WORK

6.1. Conclusions
Cardiovascular disease remains one of the top reasons for hospitalizations in the
United States and is the leading cause of death in the nation1. Tissue engineering holds
vast potential for the treatment of these diseases by regenerating the diseased tissue and
restoring structure and function to the system. Because tissue engineered options in our
research focus on autologous stem cells, it is considered a patient-tailored approach to
regenerative medicine. However, the complications presented by diabetes seem to be the
elephant in the room when it comes to hurdles in treating patients. Our tissue engineering
therapies cannot be considered patient-tailored if we cannot take into consideration the
comorbidities associated with the patient. Not only does diabetes impair the body’s
metabolic homeostasis and cause CVD, but it also complicates the reparative biomaterial
and surgical measures used treat the respective CVD. The daunting reality is that diabetes
mellitus targets the biochemistry and biological components of the human body. Our
tissue engineering paradigm includes 2 ingredients: biologic scaffolds comprised of
long-lived ECM proteins and adult autologous stem cells – both of which are just as
susceptible to AGE formation and glycoxidation as native tissues in the human body.
There is an alarming gap in the understanding of how tissue engineering approaches,
which utilize biologic scaffolds and stem cells, perform in diabetic populations. This
dilemma begs the question: how do we combat diabetes-related complications in our
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tissue engineering therapies? We believe the key to answering this question lies in the
protection of the scaffolds.
Biologic scaffolds have been proposed as an ideal source due to characteristics
such as biocompatibility, biodegradability with safe by-products, mechanical stability,
and natural ECM architecture2.

Biologic scaffolds derived from allogeneic or

xenogeneic sources have piqued much interest since they can be eliminated of cells and
immunogenic material while simultaneously retaining matrix integrity, mechanical
properties, and key cell signaling molecules3, 4. Tissue engineered bioprostheses are
promising alternatives for the creation of viable constructs in cardiovascular applications.
The balance between the resiliency of the scaffold to retain functional mechanical
properties and the biodegradability of the scaffold to allow remodeling remain a key
consideration in tissue engineering applications. The motivation underlying the use of
matrix-based vascular scaffolds lies with the attainment of the cardiovascular “niche”
which will be essential in providing the optimal environment to stem cells by presenting
cell adhesion motifs and providing physiologically relevant substrate rigidity. This niche
will drive stem cell differentiation into target cardiovascular cells when combined with
relevant biochemical and dynamic mechanical stimuli provide by a bioreactor. Though
there is an increase in the popularity of stem cell-based cardiovascular therapies, it has
been recognized that the lack of an appropriate niche for the stem cells was at fault for
poor in vivo outcomes5, 6. We believe that the ideal niche will be presented by acellular
biologic scaffolds. We have developed several optimal decellularization procedures that
wholly remove cells and antigenic proteins while preserving the natural 3D architecture,

	
  

142	
  

the major matrix components (collagen and elastin), and key basal lamina proteins
(collagen type IV, laminin, and fibronectin)7-10. By focusing on the preservation of
cardiovascular niches, we address the 3 main components of the tissue engineering
paradigm: scaffolds, stem cells, and bioreactors.
We have shown that, if left untreated, diabetes will structurally alter the biologic
scaffold thereby changing the “vascular niche” to a pathological state. Furthermore, we
have shown that diabetes leads an inflammatory insult by the host to the implanted
scaffold. These altered scaffold structural and inflammatory conditions are not conducive
to stem cell adaptation and remodeling. By treating the scaffolds with PGG, we halted
the pathological structural changes of the scaffold to preserve the vascular niche
environment as well as mitigate inflammation during host implantation. The antioxidant
properties of PGG combated glycoxidation and AGE formation thus rendering our tissue
engineered construct “diabetic-resistant” to allow for constructive stem cell remodeling,
tissue integration, and functionality.
We have also shown the potent immunomodulatory properties of adipose stem
cells (ASCs) by mitigating inflammatory cells and shifting macrophage polarization from
destructive to constructive. While the mechanisms and cytokines of immunomodulation
remains unclear, it is believed that these stem cells act as paracrine signaling factories11,
12

. We saw that ASCs are able to prevent calcification in the control rats, but not in the

diabetic rat. Asserting that inflammation and calcification are linked processes13-15, the
conclusion is that the immunomodulatory properties of ASCs inhibit the mild
inflammation-driven calcification in control rats; however, the inflammation presented by
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the diabetic rat is so severe, it overwhelms the stem cells’ propensity for
immunomodulation and continues to cause calcification. For this reason, the PGGtreatment of the scaffolds is still necessary to provide the extra means of antioxidation
and anti-inflammation. The end goal is a synergistic harmony between PGG and stem
cells to produce a practical tissue engineered device for clinical translation of
cardiovascular tissue engineering in patients with diabetes.

6.2. Alternative Perspectives
Chapter 5 focused on the differentiation of ASCs directly to target cardiovascular
cells, namely endothelial cells and smooth muscle cells. While this avenue in the tissue
engineering paradigm is still actively being pursued, recent evidence suggests that the
regenerative properties of stem cells lies in their paracrine signaling16. It is thought that,
in cell-based therapies, the paracrine mechanism of ASCs recruit relevant progenitor cells
to the local area, which then differentiate into the target cell.

Regardless of the

mechanism, the ideal end result would be the full repopulation of native host cells to the
scaffold.
Much of the research has concentrated on a fairly narrow scope of diabetes, where
the effect of hyperglycemia was mainly investigated. The small animal studies mimicked
type 1 diabetes due to the destruction of pancreatic islets by STZ and subsequent insulin
removal.

Moreover, the blood glucose levels of the diabetic rats were fairly high

(~600mg/dL) – much higher than that seen in diabetic human patients. In order to further
characterize the effects of diabetes on tissue engineering, use of animal models for type 2
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diabetes would be necessary for the in vivo studies. For in vitro studies, insulin and free
fatty acids should be added to the media to simulate hyperinsulinemia and
hyperlipidemia.
As the goal of our research is to bridge the gap from bench to bedside, realistic
efforts must be taken to meet quality and regulatory standards set forth by the FDA. As it
currently stands, stem cells receive significant scrutiny from the FDA by only allowing
“minimal manipulation” to the cells. This implies the elimination of 2-phase stem cell
culturing where stem cells are isolated and propagated in vitro, a common approach in
the laboratory. Efforts must be taken to seek ways to achieve a point-of-care approach to
tissue engineering in order to comply with the FDA as it stands today.

6.3. Recommendations for Future Work
6.3.1. Further Assessment on the Effect of Diabetes on Adipose Stem Cell Differentiation
Additional analysis on the phenotypic modulations during diabetic hASC
differentiation, diabetic hSMC culture, and diabetic hEC culture may be investigated with
protein and gene analysis. Once an adequate number of cells have been cultured, they
will be seeded into 6-well plates at 3x105 cells/well and cultured until confluency (~1x106
cells after 3-4 days). The plate will be divided for protein extraction for western blot and
RNA extraction for RT-PCR (Figure 6.1). A total of two 6-well plates (one control and
one diabetic) will be used for both hECs and hSMCs. RNA will be isolated using the
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Figure 6.1. 6-well plate layout for RT-PCR and
western blot analysis. (Row A) Cells for RNA
isolation.

(Row B) Cells for protein isolation.

This will be performed for all cell groups
discussed in Chapter 5.

RNeasy Mini Kit (QIAGEN Life Sciences) and quantified via NanoDrop (Thermo
Scientific). All samples for RT-PCR will utilize target-specific PCR primers for GAPDH
as a housekeeping gene. Primers for α-smooth muscle actin (α-SMA) and heavy chain
myosin will be used for hSMCs. Primers for CD31 and VE-Cadherin will be used for
hECs. Real-time PCR amplifications will be performed using a SYBR Green PCR kit in
a Rotorgene 3000 thermal cycler, and the 2–ΔΔCt method will be used to analyze the
relative changes in gene expression.
Total protein will be isolated from the designated wells using M-PER Mammalian
Protein Extraction Reagent (Pierce Protein Biology Products, Thermo Scientific). Total
protein will be quantified using a bicinchoninic acid assay (BCA assay) and separated
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using SDS-PAGE in Laemmli Buffer.

Western blot will be performed using BM

Chemiluminescence Western Blotting Kit (Roche Applied Science).

Proteins to be

examined will mirror that of RT-PCR: CD31, VE-Cadherin for ECs and α-SMA, heavy
chain myosin for SMCs.

6.3.2. Further Assessment on the Effect of Diabetes and Mechanical Stress on Vascular
Constructs
The same experimental setup as the bioreactor conditioned group seen in Chapter 5
will be used, however with the addition of growth factors VEGF + IGF-1 for endothelial
celldevelopment and TGF-β1 + BMP-4 for smooth muscle cell development. RNA
isolation will still be performed with the RNeasy Mini Kit using the protocol prescribed
for RNA isolation from animal tissues. Protein extraction will be performed by an
established protocol.

Briefly, the tissue will be frozen with liquid nitrogen and

pulverized with a tissue pulverizer. The sample will then be homogenized with a tissue
homogenizer in tubes containing 1mL RIPA extraction buffer (50mM Tris-HCl, 150mM
NaCl, 1mM EDTA, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS). The
homogenized solution will then sit on ice for 30 minutes and centrifuged at 12000G for
15 minutes. The supernatant (protein extract) will be collected and stored at -20°C.
SDS-PAGE and western blotting will be performed in the same fashion as with
protein extract collected using M-PER. Immunohistochemistry (IHC) will be performed
on the constructs in lieu of immunofluorescence.

In this case, constructs will be

formalin-fixed and paraffin-embedded. Sections will be cut at 5µm and dried on treated
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microscopy slides. IHC will be performed by the same protocol outlined in the previous
chapters. The same markers used for detecting smooth muscle cells and endothelial cells
from Chapter 5 will be used for gene analysis with RT-PCR and protein analysis with
western blotting.

6.3.3. Testing of Diabetic-Resistant Vascular Constructs in a Preclinical Animal Model
Yucatan mini-swine (Sinclair Bioresources) will be used to model	
  in situ vascular
graft implants. We choose these particular minipigs due to their resemblance to human
anatomy/physiology.

Also, they are the largest animals in which diabetes can be

reproducibly induced with strict glycemic control. To test for implant and surgical
viability, we will implant an acellular scaffold based from a porcine femoral artery
(developed by George Fercana, PhD) into the peripheral vasculature of a heparinized
minipig for a period of 1 week. These acellular scaffolds have been well-characterized
and is expected to create a vascular niche similar to that of decellularized carotid arteries.
Explantation analysis will involve detection for endothelial cells, smooth muscle cells,
fibroblasts, macrophages, and lymphocytes. ECM integrity will also be analyzed by
Movat’s Pentachrome staining, H&E, and Verhoeff van Gieson (VVG) stain for elastin.
Detection of calcification and osteogenic markers such as alkaline phosphatase,
osteopontin, and osteocalcin will also be performed via IHC. To gain further insight into
the hemocompatibility of the scaffold, the luminal side will be examined for platelet
activation and cell distribution by scanning electron microscopy.	
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After implant viability is established, a longer-term implant term may be
employed.

We will order a total of 12 male Yucatan minipigs from Sinclair

Bioresources. Six of these minipigs will be rendered diabetic by the supplier, while the
other 6 will remain as control specimens. Type 1 diabetes is induced using a single
alloxan injection, which partially destroys the insulin producing beta cells. Diabetes will
be confirmed by daily glucose checks and insulin administration to maintain glucose
levels within 300-400 mg/dL. Once these minipigs are stabilized, they will be shipped to
us with unilateral jugular vein access ports for painless glycemia monitoring and insulin
delivery. Upon arrival to our animal facility, Godley-Snell Animal Research Center,
animals will be allowed to acclimate 7-10 days. During this time, baseline blood glucose
levels will be established using AlphaTRAK (Abbott Laboratories, Abbott Park, IL).
Diabetic minipigs will be monitored on a daily basis for food and water consumption,
behavior, and blood glucose (checked in the a.m. before feeding time). Insulin will be
administered daily at 0.1U/kg for glycemic levels between 300-400mg/dL. For levels
<400mg/dL, daily insulin dosage will be increased by 0.1U/kg for every increase in
50mg/dL.
The same femoral artery scaffolds as discussed previously will be treated
sterilized with 0.1% peracetic acid, treated with PGG, and seeded by a process prescribed
by George Fercana. ASCs will be isolated and propagated from adipose tissue of the
minipigs via lipectomy 2 weeks prior to implant surgery. Endothelialization will be
performed in the same manner as the Dynamic ASC Differentiation Studies constructs,
with the exception that instead of 1 hour incubation per 90° turn, we will seed ~5x106
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cells per turn and incubate overnight per turn. For introducing cells into the media of the
scaffold, we will seed at a density of 5x106 cells with a syringe and a repeating dispenser
(Hamilton Company, Reno, Nevada). Cells will be injected into multiple sites along the
graft to ensure adequate, uniform coverage. The adventitia will be seeded in a drop-wise
fashion at a density of 5.5x106 cells. After all tunics have been seeded, the construct will
be cultured in static conditions for 4 days to allow for sufficient cell attachment and
adaptation. Constructs will be implanted, and each minipig will receive one autologously
cell seeded vascular scaffold, leaving the contra-lateral artery as control. A summary
chart of implants is shown in Table 6.1. Anesthesia will be administered with an
intramuscular injection of Ketamin (33 mg/kg), Acepromazine (1.1 mg/kg), Atropine
(0.02-0.05 mg/kg), and Buprenex (0.05 mg/kg). Animals will be masked with 4-5%
isoflurane in oxygen until intubation. After intubation, animals will be maintained on 23% isoflurane and connected to a ventilator. After exposure, the femoral artery will be
clamped and heparin will be administered (200 IU/kg) via IV.

The grafts will be

anastomosed in an end-to-side fashion with continuous 4-0 nylon sutures. After blood
flow is re-established, grafts will be analyzed for leaks and abnormalities. Post-operative
medications include aspirin (10 mg/kg) once a day for 2 days, Plavix (75 mg/kg) once a
day for 1 month, and subermal Fragmin (75 U/kg) once a day for 7 days. Doppler
ultrasound will be performed every week for 4 weeks to determine graft patency.
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Table 6.1. Minipig Implant Overview

	
  

After 4 weeks, animals will be sedated and anesthetized. Heparin (200 IU/kg) will be
administered and an overdose of sodium pentobarbitol (1mL / 10 lbs) will be given as a
barbiturate. Once the cessation of breathing has been determined, the graft site will be
exposed and excised together with ~20mm of native artery attached to the anastomotic
sites. All animals will receive humane care according to protocols approved by the
Clemson IACUC (AUP#2012-069, approved 1/9/2013) in compliance with NIH
guidelines.
For explant analysis we will examine mechanical properties, host cell infiltration,
AGE accumulation, calcification, matrix integrity, and inflammation.

Mechanical

properties will be determined by stress-strain characteristics from biaxial tensile tests and
thermal denaturation temperature from DSC.

AGE products such as CML and

Pentosidine will be determined via IHC and fluorescence, respectively. To determine
thrombogenicity, samples (with native artery attached) will be fixed luminal side up in
Karnovsky’s Fixative solution and imaged via SEM for platelet activation, thrombus
formation, and endothelium confluency.

Immunogenicity and inflammation will be

determined by performing IHC stains for macrophages and lymphocytes. Calcification
will be analyzed by Alizarin Red staining, and other osteogenic markers such as ALP,
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osteopontin, and osteocalcin will be analyzed by IHC. Color-based matrix stains such as
H&E, Movat’s Pentachrome, and VVG will be used to examine matrix integrity of the
graft.

Presence of tunic specific cells (endothelial cells, smooth muscle cells, and

fibroblasts) will also be examined via IHC.

6.4. References
1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford
ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard
VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH,
Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB,
McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G,
Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN,
Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics
C and Stroke Statistics S. Heart disease and stroke statistics--2014 update: a
report from the American Heart Association. Circulation. 2014;129:e28-e292.
2. Rabkin E and Schoen FJ. Cardiovascular tissue engineering. Cardiovascular
Pathology. 2002;11:305-317.
3. Liao J, Joyce EM and Sacks MS. Effects of decellularization on the mechanical
and structural properties of the porcine aortic valve leaflet. Biomaterials.
2008;29:1065-1074.
4. Badylak SF. The extracellular matrix as a biologic scaffold material.
Biomaterials. 2007;28:3587-3593.
5. Dong JD, Gu YQ, Li CM, Wang CR, Feng ZG, Qiu RX, Chen B, Li JX, Zhang
SW, Wang ZG and Zhang J. Response of mesenchymal stem cells to shear stress
in tissue-engineered vascular grafts. Acta Pharmacologica Sinica. 2009;30:530536.
6. Zhao J, Liu LQ, Wei J, Ma DY, Geng WX, Yan XR, Zhu J, Du HC, Liu Y, Li
LW and Chen FL. A Novel Strategy to Engineer Small-Diameter Vascular Grafts
From Marrow-Derived Mesenchymal Stem Cells. Artificial Organs. 2012;36:93101.
7. Chow JP, Simionescu DT, Warner H, Wang B, Patnaik SS, Liao J and
Simionescu A. Mitigation of diabetes-related complications in implanted collagen
and elastin scaffolds using matrix-binding polyphenol. Biomaterials.
2013;34:685-695.
8. Tedder ME, Liao J, Weed B, Stabler C, Zhang H, Simionescu A and Simionescu
DT. Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering. Tissue
Engineering Part A. 2009;15:1257-1268.

	
  

152	
  

9. Chuang TH, Stabler C, Simionescu A and Simionescu DT. Polyphenol-Stabilized
Tubular Elastin Scaffolds for Tissue Engineered Vascular Grafts. Tissue
Engineering Part A. 2009;15:2837-2851.
10. Schulte JB, Simionescu A and Simionescu DT. The Acellular Myocardial Flap: A
Novel Extracellular Matrix Scaffold Enriched with Patent Microvascular
Networks and Biocompatible Cell Niches. Tissue Eng Part C Methods. 2013.
11. Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R,
Johnstone BH and March KL. A population of multipotent CD34-positive adipose
stromal cells share pericyte and mesenchymal surface markers, reside in a
periendothelial location, and stabilize endothelial networks. Circulation research.
2008;102:77-85.
12. Tidball JG and Villalta SA. Regulatory interactions between muscle and the
immune system during muscle regeneration. American Journal of PhysiologyRegulatory Integrative and Comparative Physiology. 2010;298:R1173-R1187.
13. Anastasiadis K and Moschos G. Diabetes mellitus and coronary revascularization
procedures. International journal of cardiology. 2007;119:10-14.
14. Yamauchi H, Motomura N, Chung UI, Sata M, Takai D, Saito A, Ono M and
Takamoto S. Growth-associated hyperphosphatemia in young recipients
accelerates aortic allograft calcification in a rat model. Journal of Thoracic and
Cardiovascular Surgery. 2013;145:522-530.
15. Raicevic G, Najar M, Pieters K, De Bruyn C, Meuleman N, Bron D, Toungouz M
and Lagneaux L. Inflammation and Toll-Like Receptor Ligation Differentially
Affect the Osteogenic Potential of Human Mesenchymal Stromal Cells
Depending on Their Tissue Origin. Tissue Engineering Part A. 2012;18:14101418.
16. Gimble JM, Guilak F and Bunnell BA. Clinical and preclinical translation of cellbased therapies using adipose tissue-derived cells. Stem Cell Research & Therapy.
2010;1.
	
  
	
  

	
  

153	
  

